US20020156510A1 - RF therapeutic cancer apparatus and method - Google Patents

Abstract

An apparatus and method for treating cancer and other illnesses in humans and animals are described. The treatment involves the low-power, pulsed application of radio frequency tuned with precision of at least one half part per million. Alternative embodiments are described for apparatus that generates the required RF signals and applies such signals therapeutically. Laboratory data is reported, showing the successful use of the disclosed apparatus and methods to suppress and eliminate cancerous tumors in mice.

Description

FIELD OF INVENTION
• This invention generally relates to apparatus and methods for treating cancer and other illness in humans and animals, and more particularly to a therapeutic apparatus and method based upon the administration of precisely regulated, low power, pulsed electromagnetic radiation (EMR). [0001]
BACKGROUND OF THE INVENTION
• There is a considerable body of early literature regarding treatment of various illnesses with radio frequencies (RF) in the 43 MHz range. In U.S. Pat. No. 2,545,087, F. J. Hart disclosed an apparatus for treating a subject with a sequence of radio frequencies in the 43 MHz. range, applied in a step-wise fashion. These frequencies were each modulated sinusoidally at 60 Hz., and further pulsed by a second slow sinusoidal oscillator operating at 90 cycles per minute (1.5 Hz.). The RF frequencies employed by Hart were specified to three decimal places. [0002]
• The instruments available to Hart and the other researchers of his day were based on tube amplifiers, which resulted in oscillators with considerable drift that could not be precisely tuned. Hart's means for applying the RF energy to a subject most often consisted of a metal plate acting as an antenna. As a result of such oscillator drift and imprecision, and the inefficiency of the available output devices, Hart and his contemporaries were not able to conduct scientific tests with precisely controlled frequencies, or to discover optimal treatment modalities. [0003]
• Modern electronic technologies make it relatively simple to construct more precise and stable instruments than Hart had at his disposal. As a consequence, it has become possible to study systematically the potential therapeutic value of EMR. The present inventors have undertaken such studies over the course of many years, and as a result have perfected apparatus and methods which have proved effective in treating cancerous tumors in laboratory mice. The inventors believe that the same methods can be effectively adapted for human treatment. [0004]
• The present inventors have constructed apparatus designed to overcome the limitations of Hart's approach. They have further sought to establish the utility of their invention through a program of animal testing, and have in turn used the results of such testing to refine the apparatus and the methods for effectively using such apparatus. The resulting apparatus and methods, and the experimental results of applying such apparatus and methods to treat cancerous tumors in mice, will be described below. [0005]
SUMMARY OF THE INVENTION
• It is generally the object of the present invention to utilize electromagnetic radiation to provide effective treatments for cancer and other illnesses. [0006]
• It is a further object of this invention to achieve reliable and reproducible therapeutic results from EMR treatment methods by achieving precise control over the treatment frequency. [0007]
• It is also an object of the present invention to provide an efficient means of transmitting EMR from the generating means to the subject. [0008]
• It is another object of the present invention to provide an EMR treatment that may be applied at very low power levels that can cause no harm. [0009]
• These and other objects are achieved in accordance with the present invention through the use of an apparatus involving an oscillator that outputs, at a power of less than one mw, an RF frequency in the 43 MHz range, regulated and stabilized to the fifth or sixth decimal place, which is in turn modulated with a 60 Hz. 50% duty cycle square wave, which is in turn gated, again on a 50% duty cycle, at a rate of 1.167 Hz. (70 pulses per minute). [0010]
• The RF frequency is chosen for a particular subject based on the believed effectiveness of the frequency in treating the illness in question, as summarized herein. [0011]
• The modulated RF signal output by the apparatus of the present invention is applied to a flat loop of wire approximately 60 cm. long, grounded at one end and wound in five flat, concentric spiral-rectangular turns spaced about 3.175 mm. apart, the loop (herein referred to as a “treatment loop”) being mounted on an insulating layer adhesively bonded to a metal plate. [0012]
• In using this apparatus, the metal plate is placed, loop down, on the subject's body near the area to be treated. RF power is applied to the loop at one precise treatment RF frequency for at least one hour at a time. During treatment, the treatment loop is shielded from direct light and moving air currents. [0013]
• There are alternative embodiments of the invention that differ somewhat in their circuit and construction details. The first, referred to as the “Battery SCPO,” is a battery-powered “Single Crystal Pulsed Oscillator” in a metal housing with an internal quartz crystal, and an integral, externally mounted treatment loop. Each Battery SCPO is limited to a single frequency. A variation is shown (the “Mouse SCPO”) in which an SCPO is powered by an external DC power module rather than batteries. An alternate embodiment, referred to as the “Generator Embodiment”, derives its treatment signal from the modulated output of a Hewlett-Packard Model 8662A frequency generator, and supplies the signal to the treatment loop over a short coaxial cable. The frequency and power of the Generator Embodiment is easily adjusted with controls on the front panel of the 8662A frequency generator. Another alternative embodiment, also based on the HP 8662A Frequency Generator, modulates the RF signal entirely externally to the HP 8662A, and employs a specific type of coaxial cable to carry the signal from the modulator to the treatment loop. These alternative embodiments differ somewhat in their circuitry and construction details, as will be more fully described below. [0014]
• In any of the alternative embodiments, treatment is non-restrictive and utilizes a low power believed to be completely safe for humans. [0015]
• Other features and advantages of the present invention will become apparent from the following more detailed description, taken in conjunction with the accompanying drawings, which illustrate, by way of example, the principles of the invention.[0016]
BRIEF DESCRIPTION OF THE DRAWINGS
• FIGS. 1A and 1B show top and bottom external views of the Battery SCPO. [0017]
• FIG. 2 is a block diagram of the major functional units of the Battery SCPO. [0018]
• FIG. 3 is a schematic diagram of the Battery SCPO. [0019]
• FIG. 4A shows the modulation waveform of the Battery SCPO. FIGS. 4B through 4F show spectrum analyses of the output of the Battery SCPO. [0020]
• FIG. 5 is an external view of the components of the Generator Embodiment. [0021]
• FIG. 6 is a schematic diagram of the modulator circuit for the Generator Embodiment. [0022]
• FIGS. 7A and 7B show, respectively, the modulation waveform and a portion of the output waveform of the Generator Embodiment. [0023]
• FIGS. 8A and 8B show front and back views of the treatment loop used in connection with the Generator Embodiment. [0024]
• FIGS. [0025] 9A1-9J4 show the treatment housings and treatment loops used for treating mice in the experiments described herein.
• FIGS. 10 through 29 show, for each treated and control mouse involved in the inventors' experimental studies, A, the locations of the tumors (if any) that developed, B, plots (on a logarithmic scale) of the respective volumes of the various tumors as a function of time, and C, plots of the mouse's weight and hematocrit measurements as a function of time. [0026]
• FIG. 30A and B shows bar graphs of the life spans of the treated and control mice, respectively. [0027]
• FIG. 31A and B shows bar graphs of the life spans of the treated and control mice, respectively, after tumors were detected. [0028]
• FIG. 32A and B shows bar graphs of the number of tumors in the treated and control mice, respectively. [0029]
• FIG. 33A and B shows bar graphs of the outcome with respect to the tumors found in the treated and control mice, respectively. [0030]
• FIG. 34A and B shows bar graphs of the weight changes observed in the treated and control mice, respectively. [0031]
• FIG. 35A and B shows bar graphs of the maximum size of tumors observed in the treated and control mice, respectively. [0032]
• FIG. 36 is a schematic diagram for an external modulator that attaches to the radio frequency output of an [0033] HP 8662A Frequency Generator and FIG. 36A is a top view of the exterior of the device.
• FIG. 37 shows, for a mouse treated with a Generator Embodiment pulsed externally by the modulator shown in FIG. 36, A, the location of the tumor that developed, B, plots (on a logarithmic scale) of tumor volume as a function of time, and C, plots of the mouse's weight and hematocrit measurements as a function of time.[0034]
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS 1. DESIGN CONSIDERATIONS
• According to experiments conducted by the present inventors, treatment with EMR is most effective under the following conditions: [0035]
• a) The treatment frequency is selected with a precision extending to the fifth or sixth decimal point, or at least one half part per million. [0036]
• b) The frequency is extremely stable over the course of the treatment. [0037]
• c) The precise frequency chosen is held at that frequency and applied without variation for at least one hour. [0038]
• d) RF power applied to the subject is held to less than one milliwatt (mW). [0039]
• e) The EMR is applied through a coiled loop of wire, which, for treatments in the 43 MHz. Range, is approximately 60 cm. long. [0040]
• The frequencies listed in Table 1 are believed to be effective for treating the indicated maladies: [0041]

  TABLE 1
  Treatment Frequencies

  Frequency	Malady
  43,322,480	Sarcoma (generalized)
  43,322,492	Sarcoma (intestines)
  43,322,485	Sarcoma (breast)
  43,346,000	Tuberculosis (general)
  43,346,090	Tuberculosis (intestines)
  43,346,000	Tuberculosis (breast)
  43,346,050	Common cold
  43,353,800	Carcinoma (general)
  43,353,800	Carcinoma (intestines)
  43,353,850	Carcinoma (breast)
  43,353,800	Malignancy
  43,296,000	Strep
  43,351,830	Treats several diseases
  43,351,850	Treats several diseases
  43,351,855	Treats several diseases
  43,351,870	Treats several diseases
  43,352,000	Pneumonia
  43,245,000	Staph

• The foregoing list includes all of the frequencies studied by the present inventors and found to be effective. The inventors believe that different frequencies, even close to the above-stated frequencies are not effective. They have found that the effectiveness of the treatment depends critically on the precise frequency chosen, to the precision indicated herein. They have also found that steady treatment frequencies are more effective than swept or varied frequencies. [0042]
• This invention is not intended to be limited to the frequencies stated in the above table. The inventors believe that there may be other frequencies in the 43 MHz. range that the present inventors have not as yet studied, that may also be effective. Similarly, the present inventors believe that there may be effective treatment frequencies in completely different ranges, for example, at much higher frequencies. The most important factor, in the view of the present inventors, is a precisely chosen frequency steadily applied for at least an hour at a time. [0043]
2. CONSTRUCTION OF ALTERNATIVE TREATMENT DEVICES
• For twenty years we have been working to obtain the correct frequencies with which to treat the mice and also the best possible instrument (method) with which to deliver the treatment to the mouse. Some of our experiments included using two plates (a hot and ground) rather than the treatment loop. All things considered, we feel the embodiments employing treatment loop electrodes have performed the best in our experiments on the mice. [0044]
• Detailed descriptions of the alternate embodiments of the invention are set forth here to demonstrate that the principles taught in this invention are readily reducible to practice. It should be understood that these embodiments represent but a few of the possible configurations of the present invention, and that, utilizing the principles of the present invention as disclosed herein, analogous apparatus and methods may be readily devised for controlled therapeutic application of RF energy. [0045]
• A. Battery SCPO [0046]
• Top and bottom external views of the battery-operated embodiment of the treatment device are shown in FIGS. 1A and 1B. The [0047] device 100 is built in a small, self-contained rectangular metal package measuring about 7.37 cm. long, 5.46 cm. wide, and 1.78 cm. in thickness.
• [0048] Housing 110 is preferably metal. It provides mechanical protection for the apparatus and serves as a electromagnetic shield. Housing 110 is soldered shut. In battery holder 114 (Caltronics BH-124) accessible from outside the package (and which may be recessed or attached to the exterior of housing 110), the housing accommodates four standard 1.5 volt “AA” alkaline batteries 115 of approximately 1.5 volts each, which provide the electrical power for the unit.
• The underside of the device, shown in FIG. 1B, accommodates a surface mounted coil of [0049] wire 120 referred to as the “treatment loop.” One end of treatment loop 120 enters the bottom housing surface through a wire feed hole 140 in the bottom of housing 110. The other end of treatment loop is grounded at solder point 150 to the outside of housing 110. The treatment loop itself consists of five concentric, spiraled, rectangular turns of 20 AWG solid copper wire embedded in a 2 mm. (0.080 inch) thick sheet of high impact styrene 111 adhesively fastened to the bottom surface of housing 110. (Alternatively, the treatment loop may be constructed on a printed circuit board.) The windings are spaced 3.175 mm. apart and the overall dimensions of the loop are 2.858×5.258 cm.
• The [0050] treatment loop 120 has a broad radiating pattern off the coil. It is not a “focused” radiation but a spreading radiation. More signal is available from the front then off the back of treatment loop 120 (the back is shielded by a ground plane). Tests were run using a loop without the back shield but the results were not as good as with a back shield. The signal is strongest in the center since that is where the “hot” lead connects to treatment loop 120.
• The circuitry that drives [0051] treatment loop 120 is contained on a printed circuit board 190 (shown in the cutaway 180 in FIG. 1B) within housing 110. The schematic for this circuit is shown in FIG. 3. The circuit comprises two timer circuits 210 and 240, which provide approximately a 60 Hz. approximately 50% duty cycle square wave, and an approximately 70 pulse per minute (1.167 Hz.) approximate 50% duty cycle square wave, respectively. These two square waves are combined in AND gate 260 in order to produce an approximately 60 Hz. square wave pulsed at approximately 1.167 Hz., each of the 60 Hz. Square wave and the 1.167 Hz. pulse having an approximate 50% duty cycle. The waveform output by AND gate 260 is shown in FIG. 4A.
• The output of AND [0052] gate 260 is then directed through filter 270, and then to quartz crystal X1 280. Although many frequencies could be chosen from, the Battery SCPOs built to date have used a crystal cut for a third harmonic frequency of 43.351830±20 Hz., 43.351850±20 Hz., 43.351855±20 Hz. and 43.351870±20 Hz. (corresponding to base frequencies in the 14.450 MHz range). These frequencies have been found most effective for treating a broad range of maladies. The output of crystal 280 is directed to treatment loop 120.
• Viewed in further detail, the schematic diagram in FIG. 3 shows the power for the circuit derived from the four [0053] cell battery 301. This power supply feeds positive rail 302 and ground rail 303.
• The approximately 60 Hz. [0054] timing circuit 210 is based on a low power TLC 555 timer U2 311, set up as an astable multivibrator by connecting pins 2 (Trigger) and 6 (Threshold) together. Pin 1 is connected to ground 303. Pins 4 and 8 are connected to the positive supply rail 302. Pin 5 is connected to the midpoint of a voltage divider comprised of 1K resistor R9 317 (this, and all other fixed resistors referred to herein being 5%, ¼ Watt, unless otherwise specified) from the positive supply and 2.2 K resistor R8 325 to ground 302. Pin 6 is in addition connected to 1N914, 75 PIV, switching diode D2 319 forward biased from pin; to 0.22 uF (50 volt) electrolytic capacitor C3 327 to ground 303; to 47K resistor R5 321 to the wiper of 20K, 15 turn, ¾ watt adjustable resistor R7 323, one end of which is open and the other end of which is connected to pin 7. Pin 7 in addition is connected to 33K resistor R4 313 to the wiper of 20K, 15 turn, ¾ watt adjustable resistor R6 315, one end of which is open and the other end of which is connected to the positive supply rail 302. Pin 3 is the output.
• The square wave frequency and duty cycle produced by 555 Timer U2 [0055] 215 are adjusted by 20K, 15 turn, ¾ watt adjustable resistors R6 315 and R7 323 in accordance with the following formulas:
• t1 (output high)=0.693×(R4+R5+R6+R7)×C3 [0056]
• t2 (output low)=0.693×(R5+R7)×C3 [0057]
• T (total period)=t1+t2 [0058]
• f (frequency)=1/T [0059]
• D (duty cycle)=(R5+R7)/( (R4+R6)+2×(R5+R7)) [0060]
• (Units: R-Ohms; C-Farads; t, T-Seconds, f-Hz.) [0061]
• The exact frequency and duty cycle of this square wave varies with the battery voltage and precise component values The 60 Hz. and 50% duty cycle figures required for successful operation of the preferred embodiment are believed to be plus or minus 10%, based on the condition of the batteries, exact component characteristics and environmental factors such as ambient and operating temperature. [0062]
• The 1.167 Hz (70 pulse per minute) [0063] timing circuit 240 is similar to that of circuit 210. The approximately 1.167 Hz. timer circuit 240 is based on a low power TLC 555 timer U3 341, set up as an astable multivibrator by connecting pins 2 (Trigger) and 6 (Threshold) together. Pin 1 is connected to ground 303. Pins 4 and 8 are connected to the positive supply rail 302. Pin 5 is connected to the midpoint of a voltage divider comprised of 1K resistor R14 347 from the positive supply and 2.2 K resistor R15 355 to ground 303. Pin 6 is in addition connected to 1N914, 75 PIV, switching diode D3 349 forward biased from pin 7; to 10.0 uF (16 volt) electrolytic capacitor C4 357 to ground 303; to 47K resistor R11 351 to the wiper of 20K, 15 turn, ¾ watt adjustable resistor R13 353, one end of which is open and the other end of which is connected to pin 7. Pin 7 in addition is connected to 33K resistor R10 343 to the wiper of 20K, 15 turn, ¾ watt adjustable resistor R12 345, one end of which is open and the other end of which is connected to the positive supply rail 302. Pin 3 is the output.
• The output voltage of both [0064] TLC 555 timer circuits 210 and 240 is approximately 4 volts, which varies with battery supply voltage.
• The approximately 1.667 Hz. signal is combined with the approximately 60 Hz. signal in AND [0065] gate 260 which consists of 330 Ohm input resistors R2 367 and R3 367, and MPS2907 PNP transistors Q1 280 and Q2 290. FIG. 4A shows the waveform output from AND gate 260.
• From the output of the AND [0066] gate 260 is a 2.15K resistor R1 369 in series with 2 ma red light emitting diode (LED) D1 117 (Radio Shack 276-044 or equivalent) forward biased to ground 303. The LED is visible on the outside of housing 110, and is in the circuit merely to provide a visual indicator that the Battery SCPO is operating.
• The remainder of the circuit consists of 8.2 mH inductor L2 [0067] 371 (Miller 8230-18), 5.5-18 pF trimmer capacitor C2 372 (Sprague-Goodman GY A22000 or equivalent), quartz crystal X1 280 and treatment loop L1 120 to ground 303.
• [0068] Crystal X1 280 is cut so as to have a base frequency in the 14.4 MHz. Range, and a third harmonic at one of the following frequencies: 43.351830±20 Hz., 43.351850±20 Hz., 43.351855±20 Hz and 43.351830±20 Hz. Quartz crystal 280 is obtained from International Crystal Manufactures, P.O. Box 26330, Oklahoma City, Okla. 73126, and selected with great care. Other sources for crystals that have been used include CTS Corporation, Knights Division, 400 East Reimann Ave., Sandwich Ill. 60548 (which is no longer in business) and NEL Frequency Controls, Inc. 357 Beloit Street, Burlington Wis.
• Crystals are ordered approximately 25-50 at a time for each frequency, and are then individually tested on a Saunders Crystal Test System so as to allow selection of crystals with the desired frequency characteristics. For one representative crystal, driven with a reference frequency near the expected series resonance frequency, with a drive level of 2060 uWatts into 44 Ohms, with a 10 pF capacitative load, the results of this testing were as shown in Table 2. [0069]

  TABLE 2
  Exemplary Crystal Measurements

  	Parameter	Description	Value
  	Fr(Hz.)	Series resonant frequency	43,351,870 Hz.
  	Co(pF)	Shunt capacity	4.0 pF
  	Rr(Ohms)	Motional Resistance	18.2 Ohms
  	Q(k)	Quality factor	161.0 K
  	C1(fF)	Motional capacity	1.3 femtoFarads
  	L(mH)	Motional Inductance	10.7 mH
  	Fl(Hz.)	Loaded resonant frequency	43,353,820 Hz.
  	Ts(ppm/pF)	Trim sensitivity	3.2 ppm/pF
  	PWR(uWatt)	Power level	2740.0 uWatts

• No oven is used in this device. Instead, the unit is turned on for 10 minutes before use, and used in a room at an ambient temperature of approximately 72 degrees Fahrenheit. [0070]
• The output portion of the Battery SCPO involves a series LC circuit, a series crystal, and the treatment loop, which is another inductor. The large Motional Inductance of the crystal, and its very small Motional Capacitance, dominate the output circuit. This is driven by the square wave train coming out of AND [0071] gate 260. The modulation waveform output from AND gate 260, measured at the collector of transistor Q2 365, as shown in FIG. 4A, has a rise time of 18 nS and fall time approximately 120 nS. To a reasonable approximation, each 60 Hz. cycle in the modulation waveform represents a 4 volt step input with the aforementioned rise and fall times, into a series LC circuit with low series resistance. The high frequency components of the steep rise and fall of this square wave stimulates a ringing of the crystal at its characteristic base frequency and harmonics.
• The actual output of the Battery SCPO at the point of input to [0072] Treatment Loop 120 can be observed on an oscilloscope, and visibly contains RF frequencies. This was observed using an SCPO constructed with a 43.351870 Hz. Crystal. When the signal from the SCPO was input into a spectrum analyzer, a −75 dB peak is observed at the 14.448461 MHz. base crystal frequency, and a −85 dB peak is seen at the 43.351870 MHz. third harmonic frequency of the crystal. An additional, weaker RF signal is observed at 43.420000 MHz. These various spectrum analyzer scans are shown in FIGS. 4B through 4F.
• In sum, rather than using a conventional crystal oscillator circuit, the battery SCPO uses a crystal series driven by audio range square wave input pulses, in order to generate low power, yet precisely tuned, pulsed RF energy. [0073]
• The treatment device is used by applying it, treatment loop down, to the subject's body in the area desired to be treated. The unit is left in place for approximately one hour at a time. [0074]
• As indicated above, battery SCPOs have been built with crystals tuned to 43.351830±20 Hz., 43.351850±20 Hz., 43.351855±20 Hz and 43.351870±20 Hz. These frequencies were chosen because they are each believed to be useful for treating a plurality of illnesses, and because a multipurpose device is advantageous by reason of the inconvenience of changing crystals. However, there is no reason why this embodiment, would not be effective at any of the frequencies identified above as being therapeutically useful, as well as, with an appropriately tuned output element, if necessary, at any frequency found in the future to be therapeutically useful. [0075]
• A parts list for the Battery SCPO is set forth in Table 3. [0076]

  TABLE 3
  Parts List for Battery SCPO

  Ref.
  No.	Description	Source
  110	SCPO Housing	Fabricated-See text
  114	Battery Holder	Caltronics BH-124
  115	“AA” Battery 4ea	Wallgreens 1.5 V AA Ultra
  		Alkaline or equiv.
  117	Dl Indicator Light-2 mA	Radio Shack 276-044 or equiv.
  	LED Diode
  120	Treatment Loop	Fabricated-See text
  127	Backing for treatment loop	High Impact Styrene
  		0.080″ thick
  280	Quartz Crystal	ICM, CTS, or NEL-See text
  311	U2-TLC 555 Timer	Radio Shack 276-1723 or eguiv.
  313	R4 33 K +/−5% 1/4 Watt	Radio Shack 271-1341 or equiv.
  	Carbon Resistor
  315	R6 20 K 15 Turn 3/4 Watt Adj.	Radio Shack 271-340 or equiv.
  	Resistor
  317	R9 1.0 K +/−5% 1/4 Watt	Radio Shack 271-1321 or equiv.
  	Carbon Resistor
  319	D2 1N914 Switching Diode	Radio Shack 276-1122 or equiv.
  	75 PIV
  321	R5 47 K +/−5% 1/4 Watt	Radio Shack 271-1342 or equiv.
  	Carbon Resistor
  323	R7 20 K 15 Turn 3/4 Watt Adj.	Radio Shack 271-340 or equiv.
  	Resistor
  325	R8 2.2 K +/−5% 1/4 Watt	Radio Shack 271-1325 or equiv.
  	Carbon Resistor
  327	C3 0.22 uf Electrolytic	Radio Shack 272-1070 or equiv.
  	Capacitor, 50 Volts
  341	U3-TLC 555 Timer	Radio Shack 276-1723 or equiv.
  343	R10 33 K +/−5% 1/4 Watt	Radio Shack 271-1341 or equiv.
  	Carbon Resistor
  345	R12 20 K 15 Turn 3/4 Watt Adj.	Radio Shack 271-340 or equiv.
  	Resistor
  347	R14 1 K +/−5% 1/4 Watt	Radio Shack 271-1321 or equiv.
  	Carbon Resistor
  349	D3 1N914 Switching Diode	Radio Shack 276-1122 or equiv.
  	75 PIV
  351	Rl1 47 K +/−5% 1/4 Watt	Radio Shack 271-1342 or equiv.
  	Carbon Resistor
  353	R13 20 K 15 Turn 3/4 Watt Adj.	Radio Shack 271-340 or equiv.
  	Resistor
  355	R15 2.2 K +/−5% 1/4 Watt	Radio Shack 271-1325 or equiv.
  	Carbon Resistor
  357	C4 10 uf Electrolytic Capacitor,	Radio Shack 272-1436 or equiv.
  	16 Volts
  361	R2 330 Ohm +/−5% 1/4 Watt	Radio Shack 271-1315 or equiv.
  	Carbon Resistor
  363	Q1 MP52907 PNP Transistor	Radio Shack 276-2023 or equiv.
  365	Q2 MPS2907 PNP Transistor	Radio Shack 276-2023 or equiv.
  367	R3 330 Ohm +/−5% 1/4 Watt	Radio Shack 271-1315 or equiv.
  	Carbon Resistor
  369	R1 2.2 K +/−5% 1/4 Watt	Radio Shack 271-1325 or equiv.
  	Carbon Resistor
  371	L2 8.2 uH Inductor	Miller 8230-18
  372	C2 5.5-18 pF Trimmer Capacitor	Sprague-Goodman GYA22000
  		or equiv.

B. Generator Embodiment
• The alternate embodiment of the treatment device is shown in FIG. 5. It employs a [0077] model 8662A frequency generator 500 manufactured by the Hewlett-Packard Company. Frequency generator 500 has a modulation input 520, to which is connected modulator unit 540, which provides an approximate 60 Hz square wave with an approximate 50% duty cycle, which is in turn gated with an approximately 1.167 (70 pulse per minute) square wave, also with an approximately 50% duty cycle.
• The circuitry of [0078] modulator unit 540, which is more fully described below, is similar to that of the Battery SCPO, up to the point of AND gate.
• As shown in FIG. 6, power is provided by a plug-in [0079] DC power module 550, Radio Shack Cat. No. 273-1455C or equivalent, which is rated at 9 volts D.C. at 0.3 amperes. The positive lead from the module is switched through power switch SW1 542, and then directed to a 7805 5 volt voltage regulator U1 605. The negative lead of the supply is attached to the unit's ground rail 603. Both the input and output of voltage regulator U1 605 is bypassed to ground by a 0.01 uF, 500 volt disc ceramic capacitor, C1 606 and C2 607. The output, a regulated 5 volts, is applied to positive supply rail 602.
• The circuitry associated with the [0080] TLC 555 timers 611 and 641 is shown in FIG. 6, and is identical with the corresponding circuitry described above in the context of the Battery SCPO. The reference numerals “611” through “657” in FIG. 6 correspond to the identical elements “311” through “357” in FIG. 3.
• The AND gate of the modulator for the Generator Embodiment is configured identically here as in the Battery SCPO. R2, R3, Q1 and Q2 ([0081] 661, 663, 665, and 667) have the same values as in the SCPO circuit (361, 363, 365 and 367).
• The LED [0082] indicator circuit R1 669 and D1 541 differs from its counterpart in the Battery SCPO in that R1 669 is 330 Ohms rather than 2.15K. The resistor difference is for the purpose of obtaining the proper LED brightness in each circuit.
• [0083] Adjustable resistor R17 677 provides a voltage divider between positive rail 602 and ground 603. The wiper of R17 677 provides a positively offset “ground” for purposes of output to the HP 8662A. The reason for this is that the HP 8662A expects an DC signal for purposes of modulation, so this adjustment is provided to offset the output around “zero volts” as referenced to the chassis of the HP 8662A.
• The output of AND gate at the emitter of [0084] Q2 665 is connected to 8.2 uH inductor L2 671 (Miller 8230-18). The resultant signal is bypassed to ground by a relatively large electrolytic capacitor, 1.5 uF, rated at 35 volts C5 673, and then passed to the center lead of output BNC connector 521.
• The approximate modulation waveform produced by [0085] modulator unit 540 is shown in FIG. 7A. The rounding of the rise and fall of the waveform is the result of capacitor C5 673. The modulated waveform of one of the 60 Hz. cycles output by the HP 8662A is shown in FIG. 7B (the RF component in this figure is not drawn to scale). The output power of the frequency generator is less than 1 mw.
• The output of [0086] frequency generator 500 is directed through a second BNC connector 531 connected to the panel of that instrument, and through a 50 Ohm, double-shielded coaxial cable 567 (RG 174 cable, Mouser #515-156-12 or equivalent). The coaxial cable is directed to a treatment loop 565 mounted on 2.0 mm. (0.080 inch) thick styrene sheet 566 which is laminated on stainless steel plate 560. The plate has dimensions of approximately 10.2 cm. by 6.35 cm. The treatment loop 565 is a 20 AWG solid copper wire approximately 60 cm. long, wound in a flat rectangular spiral comprising five turns, with a turn-to-turn spacing of approximately 3.175 mm. and overall dimensions of 2.858×5.258 cm. The center of the loop is soldered to the center lead of coaxial cable 567. Shield 863 of coaxial cable 567 is soldered to the back of plate 560 at solder point 861. The outer end of treatment loop 565 is grounded by being soldered at solder point 570 to the loop side of plate 560. (Use A and B figures to show both sides of the plate.
• The signal from the frequency generator based embodiment of the treatment device is stronger electromagnetically than that output by battery operated [0087] device 100. It is also characterized by having only a single pure RF component at the desired frequency in the 43 MHz range. The treatment loop of generator embodiment is applied to the subject in the same manner as in the case of the battery powered embodiment.
• A parts list for the Generator Embodiment is set forth in Table 4. [0088]

  TABLE 4
  Parts List for Generator Embodiment

  Ref.
  No.	Description	Source
  500	Hewlett-Packard 8662A	Hewlett-Packard Company
  	Frequency Generator
  541	Dl Indicator Light-2 mA LED	Radio Shack 276-044 or equiv.
  	Diode
  542	SWl Power Switch	Radio Shack 275-612 or equiv.
  550	9VDC Plug-In Power Supply	Radio Shack 273-1455C or
  	Module	equiv.
  560	Treatment Loop holder	Fabricated-See text
  565	Treatment Loop	Fabricated-See text
  567	Coaxial Cable, 50 ohm,	RG174 cable Mouser
  	Shielded	#515-1156-12
  605	U 1 7805 5 Volt Voltage	Radio Shack 276-1770 or equiv.
  	Regulator IC
  606	0.01 uF Disc Ceramic Capacitor,	Radio Shack 272-131 or equiv.
  	500 Volt
  607	0.01 uF Disc Ceramic Capacitor,	Radio Shack 272-131 or equiv.
  	500 Volt
  611	U2-TLC 555 Timer	Radio Shack 276-1723 or equiv.
  613	R4 33 K +/−5% 1/4 Watt	Radio Shack 271-1341 or equiv.
  	Carbon Resistor
  615	R6 20 K 15 Turn 3/4 Watt Adj.	Radio Shack 271-340 or equiv.
  	Resistor
  617	R9 1.0 K +/−5% 1/4 Watt	Radio Shack 271-1321 or equiv.
  	Carbon Resistor
  619	D2 1N914 Switching Diode	Radio Shack 276-1122 or equiv.
  	75 PIV
  621	R5 47 K +/−5% 1/4 Watt	Radio Shack 271-1342 or equiv.
  	Carbon Resistor
  623	R7 20 K 15 Turn 3/4 Watt Adj.	Radio Shack 271-340 or equiv
  	Resistor
  625	R8 2.2 K +/−5% 1/4 Watt	Radio Shack 271-1325 or equiv.
  	Carbon Resistor
  627	C3 0.22 uf Electrolytic	Radio Shack 272-1070 or equiv.
  	Capacitor, 50 Volts
  641	U3-TLC 555 Timer	Radio Shack 276-1723 or equiv.
  643	R10 33 K +/−5% 1/4 Watt	Radio Shack 271-1341 or equiv
  	Carbon Resistor
  645	R12 20 K 15 Turn 3/4 Watt Adj.	Radio Shack 271-340 or equiv.
  	Resistor
  647	R14 1 K +/−5% 1/4 Watt	Radio Shack 271-1321 or equiv.
  	Carbon Resistor
  649	D3 1N914 Switching Diode	Radio Shack 276-1122 or equiv.
  	75 PIV
  651	Rl1 47 K +/−5% 1/4 Watt	Radio Shack 271-1342 or equiv.
  	Carbon Resistor
  653	R13 20 K 15 Turn 3/4 Watt Adj.	Radio Shack 271-340 or equiv.
  	Resistor
  655	R15 2.2 K +/−5% 1/4 Watt	Radio Shack 271-1325 or equiv.
  	Carbon Resistor
  657	C4 1Ouf Electrolytic Capacitor,	Radio Shack 272-1436 or equiv.
  	16 Volts
  661	R2 330 Ohm +/−5% 1/4 Watt	Radio Shack 271-1315 or equiv.
  	Carbon Resistor
  663	Q1 MPS2907 PNP Transistor	Radio Shack 276-2023 or equiv.
  665	02 MPS2907 PNF Transistor	Radio Shack 276-2023 or equiv.
  667	R3 330 Ohm +/−5% 1/4 Watt	Radio Shack 271-1315 or equiv.
  	Carbon Resistor
  669	R1 330 Ohm +/−5% 1/4 Watt	Radio Shack 271-1315 or equiv.
  	Carbon Resistor
  671	L2 8.2 uH Inductor	Miller 8230-18
  673	C5 1.47 uF Electrolytic	Radio Shack 272-1433 & 1434
  	Capacitor, 35 Volts
  677	R17 5 K Adj. 15 Turn 3/4 Watt	Radio Shack 271-340 or equiv.
  	Adj. Resistor

C. Alternative “Mouse SCPO” for Mouse Studies
• For purposes of the mouse studies described below, an alternative embodiment of the treatment device was developed, hereinafter referred to as the “Test Embodiment”. The Mouse SCPO consisted of an apparatus similar to the battery SCPO described above, but without a battery compartment, and powered by an external AC power adapter. The power adapter used was the same [0089] Radio Shack adapter 550 used with the modulator for the Generator Embodiment. The power supply circuit in the Mouse SCPO was identical to that used in the modulator for the Generator Embodiment, comprising the 7805 regulator U1 605, and the two 0.01 uF bypass capacitors C1 606 and C2 607. In all other respects, the Mouse SCPO was as shown in FIGS. 1, 2 and 3, using the components listed in Table 4.
• The feature lacked by the Mouse SCPO is the lack of restraint resulting from not being tethered by a wire. However, in the case of treating mice, this feature is irrelevant, since the mice must be immobilized for treatment in any event. On the other hand, the Test Embodiment had the advantage that it had no batteries to run low and to be checked and replaced. [0090]
D. Externally Pulsed Generator Embodiment
• A further alternative embodiment of the treatment apparatus was developed, herein referred to as the “Externally Pulsed Generator.” The Externally Pulsed Modulator embodiment is identical to the apparatus shown in FIG. 5, except that (1) the modulator does not attach to the Modulator Input of the [0091] HP 8662A, but rather attaches directly via a BNC connector to the RF output of the HP 8662A, (2) the modulator externally modulates the RF signal and does not utilize the internal modulation circuitry provided by the HP 8662A; and (3) the cable used to connect the modulator to the Treatment Loop is a specific type of coaxial cable, i.e., a Hewlett-Packard 10501A, 50 Ohm coaxial cable approximately 1.1 meters long.
• The modulator in the Externally Pulsed Generator embodiment contains a series solid state RF switch and associated connectors, which is pulsed by a pulsing circuit identical to that shown in FIG. 6, except that [0092] potentiometer R17 677 and capacitor C5 671 have been removed and the ground is taken from the main power supply ground rail 1303 (corresponding to rail 603 in PIG. 6). (Since there is no need to interface with the modulator input of the 8662A, there is no need for the floating ground used in the output circuit of FIG. 6.)
• The schematic diagram in FIG. 36 shows the entire circuit of this external modulator. In FIG. 36A, which shows the exterior of the device, shielded [0093] box 3601 is attached to the end of modulator housing 3600. Male BNC connector 3610 attaches directly to the RF output of the 8662A. Female BNC connector 3620 attaches to the 10501 coax which in turn leads to the Treatment Loop. (Since this unit is a self-contained external modulator, it is necessary to turn off the modulation internal to the HP 8662A using the switch for that purpose on the control panel of the HP 8662A.)
• In the RF switching circuit, the output of [0094] inductor L2 3671 is a 60 Hz/1.667 Hz. waveform 3640 (also as shown in FIG. 7A). This waveform shifts the bias on D4 3651 and D5 3652 so as to switch the RF applied to input 3653 in accordance with the pulses from L2 3671. In addition, inductor L2 3671 serves in this circuit as an RF choke keeping excessive RF from going back into the pulsing circuitry.

  TABLE 4A
  Additional Part for Externally Pulsed Generator Embodiment

  Ref.
  No.	Description	Source
  500	C5 0.01 μf capacitor	Radio Shack 272-131 or equiv.
  541	C6 0.01 μf capacitor
  542	R17 330 Ohm +/−5% ¼ Watt	Radio Shack 275-1315 or equiv.
  	Carbon Resistor
  542	R18 330 Ohm +/−5% ¼ Watt	Radio Shack 275-1315 or equiv
  	Carbon Resistor
  550	D4 1N914 Switching Diode	Radio Shack 273-1122 or equiv.
  	75 PIV
  560	Metal Box	Any suitable supplier
  565	Male BNC connector	Any suitable supplier
  567	Female BNC connector	Any suitable supplier

3. EXPERIMENTAL PROCEDURE AND RESULTS
• A controlled set of experiments were conducted during 1995 and 1996, to Jun. 25, 1996, to test the utility of the present invention with respect to the suppression and elimination of cancerous tumors, cysts, lesions, and neoplasia. The experiments were performed upon mice, by the topical application of electromagnetic (EMR) radiation at specific frequencies and intensities on a regular schedule, using the apparatus of the present invention as adapted for applying EMR to mice. We also present some additional measurements taken in 1997 with respect to one mouse that was treated using the Externally Pulsed Generator Embodiment. [0095]
• “Suppression and elimination” means that tumors, etc. that do develop are smaller in size, occur relatively infrequently and are likely to disappear over time, as opposed to untreated tumors that are larger in size, occur more frequently and are unlikely to disappear before the death of the subject. [0096]
Use of JAX Mice as Experimental Subjects
• The Jackson Laboratory at Bar Harbor, Me., 04609 supplies mice for scientific research. These special mice are “JAX Mice,” of a special inbred breed identified as C3H HeOuJ. These mice are highly abnormal, in that they are inherently very susceptible to adenocarcinoma of the mammary gland, due to the contributing factors of inherited genes, excessive hormonal stimulation, and the mouse mammary tumor virus, which is passed to the young through the mother's milk. The adenocarcinomas develop spontaneously in these mice, and the breed is characterized by a high incidence of mammary tumors by eight months of age. Our project has used “JAX Mice” type C3H HeOuJ throughout all of its research for treatment of mouse tumors, including all of the treated and control mice referred to herein. [0097]
• The JAX C3H HeOuJ mice were selected in order to provide a sensitive animal model for testing anticancer treatments. The effectiveness of various treatments for such tumors is measured by determining improvements in lifespan or other physical characteristics, such as gross appearance, health status, and other related data, of groups that have received the treatment, as against untreated controls. This manner of testing using JAX mice is accepted as a valid animal model for determining the prospective utility of cancer treatments in humans. [0098]
• In a memorandum dated Mar. 18, 1997, The Jackson Laboratory notified users of C3H/HeOuJ that it had observed an alteration over time of the development and incidence of tumors in this strain. Our experiments were primarily conducted in a much earlier time frame than that concerned in this memorandum, and we do not believe any of our experimental results were affected thereby. [0099]
Summary of Experimental Procedures and Results
• “Control” and “treated” selections of JAX mice (10 mice per group) were observed over the duration of their lives. Control mice were not exposed to the treatment procedure at all. The treated mice were exposed to EMR at the skin layer. [0100]
• The treatment given was exposure to electromagnetic radiation applied to the skin of the mouse, with the radiation held at a given frequency throughout the treatment. The duration of treatment was usually one-half to one hour, and during the treatment, the treating electrode was shielded from undue light and moving air currents. [0101]
• The data from our experiments, discussed in detail below, show that: [0102]
• 1. Treated mice live much longer than controls. [0103]
• 2. The life spans of treated mice compare favorably with life spans of normal (i.e., non-JAX) mice. [0104]
• 3. Treated mice have good health throughout their life. [0105]
• 4. Prior treatment has prevented abdominal tumor development. [0106]
• 5. When an abdominal tumor has been treated directly on the electrode it is caused to disappear. [0107]
• 6. By contrast: [0108]
• a) Tumors on control mice grow rapidly until death of the mouse, [0109]
• b) And as tumors grow, a control mouse gains weight, its hematocrit decreases and its health fails rapidly until death. [0110]
• Treatment of the particular mice herein discussed was by exposure of the JAX mice to radiation from an electrode which was energized by a low power source that was preset to provide frequencies of 43.351830 MHz, 43.351850 MHz and 43.351870 MHz. In some cases, an HP-8662A Signal Generator preset to these frequencies was used, equipped with a modulator (in all but the 1997 data, an internally coupled modulator), to provide approximately 1.667 and 60 Hz., approximately 50% duty cycle square wave pulse trains as previously described. In other cases, the same pulsed treatment frequencies were obtained with the “Mouse SCPO” embodiment described above, which contained its own modulator circuit, driving an internal quartz crystal. [0111]
• The frequencies selected, as listed in the preceding paragraph, were based on prior experiments conducted over a period of many years, during which a large number of mice were treated under varying conditions and with various treatments. The three frequencies specified in the preceding paragraph are believed by the inventors to be among the most effective frequencies for treating a range of maladies. When using the Mouse SCPO embodiment, the treatment frequency used 69% of the time (659 hours out of a total of 950) was 43351870 Hz. When using the [0112] HP 8662A signal generator for treatment, many (35) different frequencies were used.
Treatment Procedures
• One of the treated mice (OUJ-479) received treatments before a tumor appeared and lived and died tumor free. [0113]
• Treatment of the remaining mice started as soon as a tumor reached 0.07″ in length, width, and height, corresponding to an ellipsoid having a volume of 0.0295 cubic cm. (0.00018 cubic inches). The treatments for all these ten mice were every day except Sunday. The treatment frequencies are limited to a few specific frequencies within a narrow range, and the intensities are normally set to 0 dBm into a 50 ohm load. [0114]
• Due to variations among individual mice (as in other species, including humans), a treatment configuration that is effective for one subject doesn't always work for another. Frequencies of 43.351850 MHz and 43.351870 MHz were used for standard treatment on almost all of the mice. These frequencies have demonstrated good results. Treating mice with 43.351850 MHz from a signal generator and/or pulsed crystal, appears to clear up their secondary infections, and treating with 43.351870 MHz seems to restore their general health. All of the treated mice appeared to be very lively and have a very healthy skin and hair appearance. Of the mice listed below, all hematocrit values have stayed in the healthy range of 38% to 46%, and their weight basically stayed the same since they began treatment. [0115]
• Hematocrits for both the treated and the control mice were measured in accordance with the following procedure. The hematocrit was taken once a week. The mouse was placed under a heat lamp for a few minutes to cause the veins in the tail to dilate, thus making it easier to extract the blood for the sample. The amount of blood taken was about one-half of the standard 75 mm long capillary tube. The capillary tubes containing the blood are spun in a Micro-Hematocrit Centrifuge, at its “number three” marking. The capillary tubes are removed and placed in the Micro-hematocrit Tube Reader, which gives the percent of red blood cells found in the sample. [0116]
• We have observed that tumors that have reached 0.07″ in length, 0.07″ in width, 0.07″ in height are definitely a malignant growth, and benign or cystic lesions can be ruled out. Neoplasia measured under the agreed size are questionable. Almost all of the neoplasia encountered measured 0.07″, 0.07″, 0.07″ and above. [0117]
• The treatments employed a variety of treatment electrodes and housings, as shown in FIG. 9. The preferred housing was the “E” housing shown in FIG. 9A, and the preferred electrodes were the “I” electrode associated with the Mouse SCPO, FIG. 9J, and the “F” electrode used with the Hewlett-Packard signal generator, FIG. 9B. [0118]
• Tumors treated directly on the treatment electrode slowly regressed until they were gone. Tumors that were not on, or only partially on, the electrode showed a decrease in growth rate, but the tumor would steadily grow and not regress back The electrode was re-designed so that any tumor could be treated. The tumor must be directly on the electrode to receive the maximum treatment needed for complete regression of growth. Mice with lesions on their abdomen had direct contact with the electrode, and all completely regressed back to zero. We've had similar success with some mice with lesions on the neck, left leg, right neck, right side, etc. [0119]
• Since mammary tumors occur spontaneously in these mice, some mice were also treated before any tumors appeared in the hope of preventing the inevitable fate of the cancerous C3H strain, which have an almost 100% occurrence rate. At present one of the mice lived out its life span tumor free and died of old age. [0120]
Treated Mice
• The following describes our experimental results with respect to each individual treated mouse. For each mouse, there is a corresponding drawing showing where on the mouse tumors appeared, and in which the tumors are identified by a “tumor number” T-X, as well as a drawing reference numeral; a graph showing tumor volume in cubic inches vs. time in days; a graph showing mouse weight in grams and hematocrit readings vs. time in days; and an Appendix setting forth all experimental measurements taken with respect to the mouse. [0121]
• Each tumor growth graph (FIGS. 10B, 11B, etc.) shows the size of each tumor, in cubic inches, on the mouse in question as a logarithmic function of days after the appearance of the subject's first tumor. Tumor volume, in cubic inches, was calculated based on the assumption that the tumor was approximately an ellipsoid, and had a volume equal to ½ length×½ width×height×2.094. [0122]
• Each weight and hematocrit graph (FIGS. 10C, 11C, etc.) shows, in two separate plots, (a) the weight of the mouse, in grams, and (b) the subject's hematocrit values (percentage of red blood cells) as a linear function of days after the appearance of the subject's first tumor. [0123]
• The detailed data collected with respect to each treated mouse is shown in tabular form in Appendices A-1, A-2, etc. attached hereto, and the data collected with respect to each control mouse is shown in tabular form in Appendices, B-1, B-2, etc. attached hereto. The data with respect to one mouse tested in 1997 is shown in tabular form in Appendix C. [0124]
Example 1—Treated Mouse OUJ456
• [0125]

  TABLE 5
  Treatment Summary for OUJ-456

  	Date of Birth	09/08/94
  	Date Died	08/04/95
  	Lived	310 days
  	Treated	91 days
  	Tumor measurements started	05/05/95
  	Tumor measurements taken for	91 days

• This mouse lived 219 days before any tumor appeared. Notice (in FIG. 10B) that T-2 [0126] 1002, which was hard to reach with our electrodes, grew, but at a slower rate than a typical control mouse. As will be seen from this and the other examples herein, treated mice live three times longer than controls after a tumor appears.
Example 2—Treated Mouse OUJ-470
• [0127]

  TABLE 6
  Treatment Summary for OUJ-470

  	Date of Birth	03/03/94
  	ate Died	07/30/95
  	Lived	515 days
  	Treated	257 days
  	Tumor measurements started	11/16/94
  	Tumor measurements taken for	257 days

• This mouse lived 258 days before any tumor appeared. Notice (in FIG. 11B) that T-1 [0128] 1101 appeared and went away at two different times. T-2 1102 appeared for a short period. T-3 1103 appeared when this mouse was 496 days old. This is one of the longest-lived mice in our experiments.
Example 3—Treated Mouse OUJ-471
• [0129]

  TABLE 7
  Treatment Summary for OUJ-471

  	Date of Birth	03/03/94
  	Date Died	07/20/95
  	Lived	504 days
  	Treated	199 days
  	Tumor measurements started	01/02/94
  	Tumor measurements taken for	199 days

• This mouse lived 305 days before any tumor appeared. Notice that T-1 [0130] 1201 and T-2 1202 appeared for a short period. Notice (in FIG. 12C) the steady weight at 30 grams and constant high hematocrit percentage readings. This was also one of our longest-lived mice.
Example 4—Treated Mouse OUJ-473
• [0131]

  TABLE 8
  Treatment Summary for OUJ-473

  	Date of Birth	03/03/94
  	Date Died	07/28/95
  	Lived	514 days
  	Treated	211 days
  	Tumor measurements started	12/29/94
  	Tumor measurements taken for	211 days

• As an experiment, we treated this mouse before any tumors appeared. This mouse never developed any tumors (FIG. 13B). She lived 303 days before we started treatments. Notice (in FIG. 13C) the steady weight at 28 grams. This was also one of our longest-lived mice. [0132]
Example 5—Treated Mouse OUJ-475
• [0133]

  TABLE 9
  Treatment Summary for OUJ-475

  	Date of Birth	03/03/94
  	Date Died	07/28/95
  	Lived	514 days
  	Treated	256 days
  	Tumor measurements started	11/14/94
  	Tumor measurements taken for	256 days

• This mouse lived 258 days before any tumor appeared. Notice (FIG. 14B) that T-1 [0134] 1401 and T-2 1402 appeared for a short period. Notice (FIG. 13C) the steady weight at 30 grams and quite-constant high hematocrit percentage readings. This was also one of our longest-lived mice.
Example 6—Treated Mouse OUJ-496
• [0135]

  TABLE 10
  Treatment Summary for OUJ-496

  	Date of Birth:	12/21/94
  	Date Died:	01/05/96
  	Lived:	380 days
  	Treated:	113 days
  	Tumor measurements
  	09/15/95
  	started:
  	Tumor measurements taken	113 days
  	for:

• This mouse lived 267 days before any tumor appeared. Notice (FIG. 15B) that T-1 [0136] 1501 and T-5 1505 appeared and left. Notice (FIG. 15C) the steady weight at 30 grams and high hematocrit percentage readings. Even with all these tumors, this mouse stayed healthy until the end and lived a long time.
Example 7—Treated Mouse OUJ-506
• [0137]

  TABLE 11
  Treatment Summary for OUJ-506

  	Date of Birth:	01/05/95
  	Still living:	06/25/96
  	Lived:	537 days
  	Treated (and/or took data):	250 days
  	Tumor measurements
  	10/19/95
  	started:
  	Tumor measurements taken	250 days
  	for:

• This mouse lived 287 days before any tumor appeared. Notice (FIG. 16B) that T-1 [0138] 1601, T-2 1602, and T-3 1603 appeared for a short period. After 170 days, T-2 1602 reappeared. Notice (FIG. 16C) the constant high hematocrit percentage readings. This was our longest-lived mouse, and it had a long healthy life.
Example 8—Treated Mouse OUJ-516
• [0139]

  TABLE 12
  Treatment Summary for OUJ-516

  	Date of Birth:	02/02/95
  	Date Died:	03/26/96
  	Lived:	418 days
  	Treated:	240 days
  	Tumor measurements	07/31/95
  	started:
  	Tumor measurements taken	240 days
  	for:

• This mouse had a record number of tumors, many of which were not on the abdomen (FIG. 17A). After treatment all tumors disappeared except T5 [0140] 1705, T7 1707, T8 1708, and T9 1709 (FIG. 17B). In spite of the large number of tumors, she lived 418 days.
Example 9 - Treated Mouse OUJ-526
• [0141]

  TABLE 13
  Treatment Summary for OUJ-526

  	Date of Birth:	02/02/95
  	Date Died:	04/12/96
  	Lived:	435 days
  	Treated:	168 days
  	Tumor measurements
  	10/28/95
  	started:
  	Tumor measurements taken	168 days
  	for:

• This mouse had three tumors which disappeared and never returned (FIG. 18B). She lived 267 days before any tumor appeared. T4 [0142] 1804 and T5 1805 grew together as one tumor. Hematocrit percent (FIG. 18C) stayed quite high throughout her life.
Example 10—Treated Mouse OUJ-650
• [0143]

  TABLE 14
  Treatment Summary for OUJ-650

  	Date of Birth:	04/04/95
  	Still living:	06/25/96
  	Lived:	448 days
  	Treated:	195 days
  	Tumor measurements
  	12/13/95
  	started:
  	Tumor measurements taken	195 days
  	for:

• This mouse had three tumors, all of which disappeared and never re-appeared (FIG. 19B). Her hematocrit percent and remained high and her weight stayed constant throughout the measurement period (FIG. 19C). [0144]
Control Mice
• The controls listed below all had spontaneous occurrences of multiple tumors that arose in various areas of the mammary gland region, and also had a very short survival time once the tumors appeared, usually around a two-month period. [0145]
• None of the control mice in this study received EMR treatments or any other type of intervention methods. Daily weight and tumor measurements and observations were noted, as well as hematocrits to indicate the mouse's present health status at the time. These non-treated mice appeared to be in excellent health and appearance when the tumor remained small and didn't metastasize, but as the malignancy progressed and spread to other tissues, the effects on the mouse were readily seen. [0146]
• The tumor measurements showed a rapid increase in tumor size that continuously rose almost every day, accompanied with a steady gain in weight, especially, with the arrival of new neoplasms. The hematrocrit steadily lowers with the increase in tumor measurements. Other side-effects were also observed in the controls, such as, the coat began to show a rougher appearance, the back bone protruded out, they appeared to be malnourished, and the normal curiosity and physical activity seen in healthy mice were absent. The neoplasms' appearance also changed once the tumor reached a certain size, usually around 1.5 cm. in diameter and up. They usually would start to appear red and puffy, which would deepen in color showing areas of purple and black sores, which eventually ulcerated with severe bleeding. Some of the mice also appeared to get secondary infections once the tumor ulcerated, accompanied by the draining of clear fluid and WBC present in the wound. When the tumor reached a diameter of 1.8 cm., and the hematocrit value was 25% or lower, the mouse usually died within a couple of days. [0147]
• As will be illustrated by the experimental data that follows, the characteristics of all control mice observed in the lab included the following: a rapid growth rate of tumors shown in the increasing size measurements and weight gain; metastasis; and continual decrease in hematocrit with the increasing tumor measurements. All the above symptoms affect the mouse's gross appearance, tumor appearance and shortened survival span once the tumors appear. This is reflected in the data that follows in the controls' rate of growth, and their decrease in hematocrit and length of survival period. [0148]
Example 11—Control Mouse A-486
• [0149]

  TABLE 15
  Summary for A-486

  	Date of Birth:	04/04/95
  	Date died:	06/25/96
  	Lived:	448 days
  	Treated:	Not treated
  	Tumor measurements	08/09/95
  	started:
  	Tumor measurements taken	97 days
  	for:

• This mouse had one tumor which grew very rapidly to a large size (FIG. 20B). She had another tumor which appeared for 8 days. Her weight started to increase near the end, and the low hematocrit readings indicated a poor general health (FIG. 20C). [0150]
Example 12—Control Mouse A-488
• [0151]

  TABLE 16
  Summary for A-488

  	Date of Birth:	11/28/94
  	Date died:	11/13/95
  	Lived:	350 days
  	Treated:	Not treated
  	Tumor measurements	07/20/95
  	started:
  	Tumor measurements taken	116 days
  	for:

• This mouse had one tumor (T1 [0152] 2101) which didn't change much for forty days then grew rapidly (FIG. 21B). T-2 2102 came in and left after 32 days. T-3 2103 stayed constant in size for about 90 days, then grew rapidly.
Example 13—Control Mouse A-490
• [0153]

  TABLE 17
  Summary for A-490

  	Date of Birth:	12/19/94
  	Date died:	11/29/95
  	Lived:	345 days
  	Treated:	Not treated
  	Tumor measurements	10/11/95
  	started:
  	Tumor measurements taken	50 days
  	for:

• This mouse had four rapidly growing tumors and lived only fifty days after the first tumor appeared (FIG. 22B). After 20 days her weight increased and hematocrit reading steadily dropped (FIG. 22C). [0154]
Example 14—Control Mouse A-492
• [0155]

  TABLE 18
  Summary for A-492

  	Date of Birth:	12/19/94
  	Date died:	12/29/95
  	Lived:	375 days
  	Treated:	Not treated
  	Tumor measurements	09/15/95
  	started:
  	Tumor measurements taken	105 days
  	for:

• At 375 days, this is the longest lived control mouse. (Nine of our ten treated mice lived longer.) She had two tumors that left (FIG. 23B). But, after thirty days, T3 [0156] 2303 and T4 2304 appeared and started to grow very rapidly. Her hematocrits dropped rapidly after 70 days of measurements (FIG. 23C).
Example 15—Control Mouse A-500
• [0157]

  TABLE 19
  Summary for A-500

  	Date of Birth:	01/04/95
  	Date died:	10/11/95
  	Lived:	280 days
  	Treated:	Not heated
  	Tumor measurements
  	09/15/95
  	started:
  	Tumor measurements taken	26 days
  	for:

• This mouse did not live very long and was observed only twenty-six days then she died. Tumors grew rapidly (FIG. 24B) and hematocrits were quite low (FIG. 24C). [0158]
Example 16—Control Mouse A-538
• [0159]

  TABLE 20
  Summary for A-538

  	Date of Birth:	03/24/95
  	Date died:	01/15/96
  	Lived:	297 days
  	Treated:	Not treated
  	Tumor measurements	10/19/95
  	started:
  	Tumor measurements taken	88 days
  	for:

• This mouse had three large tumors (FIG. 25B) and rapid weight increase and very low hematocrit percent readings (FIG. 25C). This mouse also did not live very long and was quite unhealthy. [0160]
Example 17—Control Mouse A-540
• [0161]

  TABLE 21
  Summary for A-540

  	Date of Birth:	03/25/95
  	Date died:	01/02/96
  	Lived:	283 days
  	Treated:	Not treated
  	Tumor measurements	11/15/95
  	started:
  	Tumor measurements taken	48 days
  	for:

• This mouse had one tumor that grew to a large size and grew fast (FIG. 26B). Low hematocrits caused this mouse to die in a short period (FIG. 26C). [0162]
Example 18—Control Mouse A-542
• [0163]

  TABLE 22
  Summary for A-542

  	Date of Birth:	03/25/95
  	Date died:	01/18/96
  	Lived:	299 days
  	Treated:	Not treated
  	Tumor measurements	11/27/95
  	started:
  	Tumor measurements taken	52 days
  	for:

• This mouse had two tumors that grew to a large size and grew fast (FIG. 27B). Weight continued to increase as the tumors grew (FIG. 27C). A tumor size of 0.1 to 0.5 cubic inches on a mouse this small is quite a burden for the mouse. They do not survive for long with tumors that size. [0164]
Example 19—Control Mouse A-592
• [0165]

  TABLE 23
  Summary for A-592

  	Date of Birth:	06/27/95
  	Date died:	02/14/96
  	Lived:	232 days
  	Treated:	Not heated
  	Tumor measurements
  	01/19/96
  	started:
  	Tumor measurements taken	26 days
  	for:

• This mouse had one tumor that grew to a one cubic inch in size and grew fast (FIG. 28B). Rapid decline in hematocrits caused this mouse to die in a short period (FIG. 28C). Notice the rapid increase in weight: the mouse nearly doubled in weight in twenty days. This was a very short-lived mouse. [0166]
Example 20—Control Mouse A-594
• [0167]

  TABLE 24
  Summary for A-594

  	Date of Birth:	06/27/95
  	Date died:	02/15/96
  	Lived:	233 days
  	Treated:	Not treated
  	Tumor measurements	01/12/96
  	started:
  	Tumor measurements taken	34 days
  	for:

• This mouse also had one tumor that grew to a large size and grew fast (FIG. 29B). Rapidly declining hematocrits caused this mouse to die in a short period (FIG. 29C). This is one of the shortest-lived control mice of the group. [0168]
Experimental Conclusions
• Our principal conclusion, based on the experiments described above, is that the cancer-prone JAX mice benefited considerably from the therapeutic apparatus and method of the present invention. The subsidiary experimental conclusions that support this assertion are as follows: [0169]
1. Total Days of Life: Treated Mice Live 50% Longer
• The bar-graphs in FIG. 30 show that the treated mice lived approximately 50% longer on average than the controls. Each bar indicates: Days of Waiting [0170] 3001, Days of Treatment (or Measurement) 3002, 3003, and Total Days Of Life 3004.
• The data underlying FIG. 30 (as well as FIGS. 31 and 32, discussed below) is presented below in tabular form. [0171]

  TABLE 25
  Days of Life, Measurement, and Number of Tumors

  	NON
  	MEASURED	MEASURED	QTY OF
  SUBJECT	DAYS	DAYS	TUMORS	TOTAL LIFE
  OUJ-456	219	91	2	310
  OUJ-496	268	112	6	380
  OUJ-650	253	195	3	392
  OUJ-516	179	239	9	418
  OUJ-526	268	167	5	435
  OUJ-506	287	250	5	481
  OUJ-471	305	199	2	504
  OUJ-473	301	211	0	512
  OUJ-475	256	256	2	512
  OUJ-470	258	256	3	514
  Totals:	2594	1976	37	4,458
  A-592	206	26	3	232
  A-594	199	34	1	233
  A-500	254	26	3	280
  A-540	235	48	1	283
  A-538	209	88	3	297
  A-542	247	52	2	299
  A-490	296	49	4	345
  A-488	234	116	4	350
  A-486	255	97	2	352
  A-492	270	105	4	375
  Totals:	2405	641	27	3,046

2. Starting Treatment After First Tumor Appears: Treated Mice Live More than 300% Longer
• FIG. 31 shows that after the first tumor appeared, the treated mice lived longer than the control mice. The bars in these graphs represent Days of Treatment for treated mice or Days of Measurement for control mice. The data underlying FIG. 31 is set forth in Table 25 above. [0172]
3. The Treated Mice Had More Tumors (by 37%), But They Lived Longer
• FIG. 32 shows the number of tumors that developed in each mouse. It must be noted that even though there were 37% more tumors in the treated mice, they lived longer than the controls. The data underlying FIG. 32 is set forth in Table 25 above. [0173]
4. Tumors that Appeared were Five Times More Likely to Disappear in the Treated Mice than in the Controls
• FIG. 33 shows the total number of tumors in each mouse, and those tumors that disappeared or were cured and the remaining tumors at the death of each mouse. (Note: OUJ-506 and OUJ-650 were still living as of Jun. 25, 1996, when this data was compiled.) [0174]
• The data underlying FIG. 33 is set forth in Table 26 below. [0175]

  TABLE 26
  Tumors That Disappeared

  	MEAS-	REMAIN-	CURED/		NON
  	URED	ING	GONE	TOTAL	MEASURED
  SUBJECT	DAYS	TUMORS	TUMORS	LIFE	DAYS
  OUJ-456	91	1	1	310	219
  OUJ-496	112	3	3	380	268
  OUJ-650	195	0	3	448	253
  OUJ-516	239	4	5	418	179
  OUJ-526	167	2	3	435	268
  OUJ-506	250	2	3	537	287
  OUJ-471	199	0	2	504	305
  OUJ-473	211	0	0	512	301
  OUJ-475	256	0	2	512	256
  OUJ-470	256	1	2	514	258
  Totals:	1976	13	24	4,570	2594
  A-592	26	3	0	232	206
  A-594	34	1	0	233	199
  A-500	26	3	0	280	254
  A-540	48	1	0	283	235
  A-538	88	3	0	297	209
  A-542	52	2	0	299	247
  A-490	49	4	0	345	296
  A-488	116	3	1	350	234
  A-486	97	1	1	352	255
  A-492	105	2	2	375	270
  Totals:	641	23	4	3,046	2405

5. The Weight of the Treated Mice Remained Stable, Whereas the Control Mice Markedly Gained Weight
• FIG. 34 shows that the treated mice maintain their weight on average, while the control mice gain considerable weight due to tumor growth. (Note: The weight change shown is the last 10 day weight average minus the first 10 day weight average of each mouse.) [0176]
• The data underlying FIG. 34 is set forth in Table 27 below. [0177]

  TABLE 27
  Comparative Weight Changes

  	Weight
  	Change

  	Treated
  	Mouse
  	OUJ-456	5.85
  	OUJ-526	2.37
  	OUJ-470	1.31
  	OUJ-471	−0.15
  	OUJ-473	−1.36
  	OUJ-475	−2.22
  	OUJ-506	−0.66
  	OUJ-650	−0.15
  	OUJ-516	0.07
  	OUJ-496	−4.92
  	Totals:	0.14
  	Control
  	Mouse
  	A-592	20.31
  	A-538	15.42
  	A-490	14.32
  	A-542	9.97
  	A-486	6.54
  	A-540	6.15
  	A-492	3.98
  	A-500	0.02
  	A-488	−1.73
  	A-594	−4.92
  	Totals:	70.06

6. The Control Mice Had More Large Tumors
• FIG. 35 shows the maximum sizes of each tumor on the twenty different mice. Some of these tumors disappeared. The vertical scale is tumor size in cubic inches. There were 37 treated and 27 control tumors but this graph shows the 27 largest treated tumors and all 27 control tumors. [0178]
• The data underlying FIG. 35 is set forth in Tables 28A and B below. [0179]

  TABLE 28A
  Comparison of Maximum Tumor Size (in cubic inches)

  Treated
  Subject	Tumor
  1	Tumor 2	Tumor 3	Tumor 4	Tumor 5	Tumor 6	Tumor 7	Tumor 8	Tumor 9

  OUJ-456	0.00001413	0.27320000
  OUJ-470	0.00017960	0.00001413	0.00954900
  OUJ-471	0.00026180	0.00009161
  OUJ-473
  OUJ-475	0.00001413	0.00036650
  OUJ-496	0.00117800	0.03799000	0.00633200	0.01099000	0.00015390	0.00029680
  OUJ-506	0.00001413	0.01866000	0.00001413	0.00017960	0.01682000
  OUJ-516	0.00001413	0.00017960	0.00006544	0.00653300	0.08179000	0.00048370	0.03624000	0.05560000	0.17990000
  OUJ-526	0.00001413	0.00082920	0.00006544	0.06579000	0.00533600
  OUJ-650	0.00241900	0.00006544	0.00006544
  Total	0.00410800	0.33140000	0.01609000	0.08349000	0.10410000	0.00078050	0.03624000	0.05560000	0.17990000
  Average	0.00045650	0.03682000	0.00268200	0.02087000	0.02603000	0.00039030	0.03624000	0.05560000	0.17990000

• [0180]

  TABLE 28B
  Comparison of Maximum Tumor Size (in cubic inches)

  Control
  Subject	Tumor
  1	Tumor 2	Tumor 3	Tumor 4

  A-486	0.43920000	0.00001413
  A-488	0.41790000	0.00619300	0.00762200	0.01493000
  A-490	0.20800000	0.47080000	0.04913000	0.02954000
  A-492	0.00052350	0.00006544	0.10690000	0.16280000
  A-500	0.06478000	0.04252000	0.20560000
  A-538	0.56350000	0.32310000	0.03216000
  A-540	0.39520000
  A-542	0.36820000	0.13700000
  A-592	0.81920000	0.00419200	0.01504000
  A-594	0.19090000
  Total	3.46700000	0.98380000	0.41640000	0.20730000
  Average	0.34670000	0.12300000	0.06940000	0.06910000

Test of Externally Pulsed Generator
• FIG. 37 shows the results of treating mouse OUJ-738 in 1997 with the Externally Pulsed Generator embodiment. Treatment was with the [0181] HP 8662A frequency generator externally modulated with the modulator shown in FIG. 36, coupled to a treatment loop as shown in FIGS. 8A and 8B deployed in the “E” housing shown in FIG. 9A. The corresponding experimental data is shown in Appendix C.
• FIG. 37A shows that a [0182] single tumor T1 3701 developed on this mouse in the left arm position. This position is difficult to treat because it is out of the way and as a consequence it is difficult to position the treatment electrode close to the tumor. Nevertheless, the results with this mouse were extremely good for the period of testing. As shown in FIG. 37B, the tumor stayed small for the entire period, and as shown in FIG. 37C, the weight was stable and the hematocrits remained high. The data extends up to a few days prior to the filing of this application, and at the end of this period the mouse was alive and healthy.
• In addition, data were compiled in 1997 with respect to tumors that disappeared after treatment with the generator embodiment. This data, which otherwise appears in the Figures hereto, is as follows: [0183]

  TABLE 29
  Disappearance of Tumors on Mice Treated with HP 8662A Frequency
  Generator Embodiment

  Treated	Tumor	Tumor	Tumor	Tumor	Tumor	Tumor
  Mouse #
  	1	2	3	4	5	6
  OUJ-650	Yes	Yes	Yes
  OUJ-526	Yes	Yes	Yes
  OUJ-516	Yes	Yes	Yes	Yes		Yes
  OUJ-506	Yes	Yes	Yes	Yes
  OUJ-496	Yes				Yes
  OUJ-471	Yes	Yes
  OUJ-470	Yes	Yes
  OUJ-456	Yes

• It is apparent from the foregoing that a new treatment has been developed which has shown great effectiveness in treating cancer and other illnesses in laboratory mice and is believed to be a promising treatment for humans. While only presently preferred embodiments have been described in detail, it will be apparent to those skilled in the art that certain changes and modifications can be made without departing from the scope of the invention, as defined in the following claims. [0184]
APPENDICES A1-A10 TREATED MOUSE DATA
• [0185]

  Index (Pages numbered on back)

  Appendix	Subject	Pages
  A1	OUJ
  456	48-49
  A2	OUJ	470	50-55
  A3	OUJ	471	56-59
  A4	OUJ	473	60-63
  A5	OUJ	475	64-69
  A6	OUJ	496	70-71
  A7	OUJ	506	72-75
  A8	OUJ	516	76-83
  A9	OUJ	526	84-91
  A10	OUJ	650	92-93

• [0186]

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  

  
APPENDICES B1-B10 CONTROL MOUSE DATA
• [0187]

  Index (Pages numbered on back)

  Appendix	Subject	Pages
  B1	A
  486	95-97
  B2	A	488	98-100
  B3	A	490	101-102
  B4	A	492	103-105
  B5	A	500	106
  B6	A	538	107-108
  B7	A	540	109-110
  B8	A	542	111-112
  B9	A	592	113
  B10	A	594	114

• [0188]

  	A-486

  DOB Nov. 27, 1994

  A-486 LT ARM T-1

  LT INR LEG T-2

  WEIGHT

  HEMA-

  DAY	DATE	X	Y	Z	EVOL	X	Y	Z	EVOL	GRAMS	TOCRIT
  1	9-Aug	0.050	0.050	0.050	.00007				.00000	28.78
  2	10-Aug	0.050	0.050	0.050	.00007				.00000	28.31
  3	11-Aug	0.060	0.060	0.060	.00011				.00000	29.08
  4	12-Aug	0.060	0.060	0.060	.00011				.00000	29.08
  5	13-Aug	0.070	0.070	0.070	.00018				.00000	28.99
  6	14-Aug	0.080	0.080	0.070	.00023				.00000	28.89
  7	15-Aug	0.080	0.080	0.070	.00023				.00000	28.68
  8	16-Aug	0.080	0.080	0.070	.00023				.00000	28.86
  9	17-Aug	0.080	0.080	0.070	.00023				.00000	28.85
  10	18-Aug	0.080	0.080	0.060	.00020				.00000	28.83
  11	19-Aug	0.080	0.080	0.060	.00020				.00000	28.82
  12	20-Aug	0.080	0.080	0.060	.00020				.00000	28.80
  13	21-Aug	0.080	0.080	0.050	.00017				.00000	28.79
  14	22-Aug	0.080	0.080	0.050	.00017				.00000	28.59
  15	23-Aug	0.080	0.080	0.050	.00017				.00000	28.65
  16	24-Aug	0.080	0.080	0.050	.00017				.00000	28.75
  17	25-Aug	0.080	0.080	0.050	.00017				.00000	28.76
  18	26-Aug	0.090	0.090	0.050	.00021				.00000	31.66
  19	27-Aug	0.100	0.100	0.050	.00026				.00000	30.83
  20	28-Aug	0.100	0.100	0.050	.00026				.00000	29.99
  21	29-Aug	0.110	0.110	0.050	.00032				.00000	29.16
  22	30-Aug	0.110	0.110	0.050	.00032				.00000	28.32
  23	31-Aug	0.124	0.126	0.055	.00053				.00000	28.36
  24	1-Sep	0.139	0.141	0.080	.00082				.00000	28.41
  25	2-Sep	0.153	0.157	0.095	.00119				.00000	28.45
  26	3-Sep	0.167	0.173	0.110	.00166				.00000	28.50
  27	4-Sep	0.181	0.189	0.125	.00224				.00000	28.54
  28	5-Sep	0.196	0.204	0.140	.00293				.00000	28.59
  29	6-Sep	0.210	0.220	0.155	.00375				.00000	26.63
  30	7-Sep	0.224	0.236	0.170	.00470				.00000	28.68
  31	8-Sep	0.239	0.251	0.185	.00581				.00000	28.72
  32	9-Sep	0.253	0.267	0.200	.00707				.00000	28.76
  33	10-Sep	0.267	0.283	0.215	.00850				.00000	28.81
  34	11-Sep	0.281	0.299	0.230	.01012				.00000	28.85
  35	12-Sep	0.296	0.314	0.245	.01192				.00000	28.90
  36	13-Sep	0.310	0.330	0.260	.01392				.00000	28.94
  37	14-Sep	0.300	0.360	0.270	.01527				.00000	28.66
  38	15-Sep	0.200	0.200	0.100	.00209				.00000	28.78
  39	16-Sep	0.280	0.400	0.160	.00938				.00000	28.98
  40	17-Sep	0.220	0.250	0.230	.00662				.00000	29.86
  41	18-Sep	0.390	0.500	0.290	.02960				.00000	29.83
  42	19-Sep	0.400	0.510	0.290	.03097				.00000	30.41
  43	20-Sep	0.430	0.450	0.340	.03444				.00000	30.78
  44	21-Sep	0.460	0.450	0.350	.03793				.00000	29.51
  45	22-Sep	0.460	0.470	0.400	.04527				.00000	30.27
  46	23-Sep	0.460	0.480	0.430	.04970				.00000	30.12
  47	24-Sep	0.460	0.480	0.430	.04970				.00000	29.59
  48	25-Sep	0.470	0.480	0.430	.05078				.00000	29.21
  49	26-Sep	0.470	0.500	0.470	.05782				.00000	30.47
  50	27-Sep	0.490	0.540	0.480	.06649				.00000	30.21
  51	28-Sep	0.490	0.570	0.530	.07749				.00000	29.77
  52	29-Sep	0.500	0.570	0.500	.07460				.00000	30.29
  53	30-Sep	0.510	0.570	0.500	.07609				.00000	30.23
  54	1-Oct	0.530	0.580	0.500	.08046				.00000	30.15
  55	2-Oct	0.540	0.580	0.500	.08198				.00000	30.09	41
  56	3-Oct	0.560	0.570	0.480	.08021				.00000	29.98
  57	4-Oct	0.560	0.580	0.520	.08842				.00000	31.33
  58	5-Oct	0.580	0.630	0.520	.09947	0.030	0.030	0.030	.00001	30.97
  59	6-Oct	0.590	0.640	0.550	.10872	0.030	0.030	0.030	.00001	31.42
  60	7-Oct	0.600	0.640	0.560	.11257	0.030	0.030	0.030	.00001	31.15
  61	8-Oct	0.600	0.640	0.560	.11257	0.030	0.030	0.030	.00001	30.95
  62	9-Oct	0.610	0.640	0.570	.11649	0.030	0.030	0.030	.00001	30.71
  63	10-Oct	0.680	0.660	0.570	.12292	0.030	0.030	0.030	.00001	32.67	30
  64	11-Oct	0.700	0.690	0.610	.15424	0.030	0.030	0.030	.00001	31.88
  65	12-Oct	0.730	0.720	0.640	.17610	0.010	0.010	0.010	.00000	31.52
  66	13-Oct	0.680	0.760	0.670	.18127	0.010	0.010	0.010	.00000	32.26
  67	14-Oct	0.700	0.780	0.670	.19151				.00000	32.28
  68	15-Oct	0.720	0.800	0.670	.20203				.00000	32.30
  69	16-Oct	0.730	0.620	0.670	.20996				.00000	32.31
  70	17-Oct	0.780	0.820	0.660	.22099				.00000	33.40
  71	18-Oct	0.800	0.780	0.530	.17313				.00000	28.67
  72	19-Oct	0.740	0.740	0.540	.15480				.00000	28.94
  73	20-Oct	0.750	0.760	0.530	.15815				.00000	29.96
  74	21-Oct	0.750	0.760	0.530	.15815				.00000	29.96
  75	22-Oct	0.790	0.770	0.550	.17514				.00000	30.90
  76	23-Oct	0.800	0.790	0.560	.18528				.00000	31.45
  77	24-Oct	0.800	0.810	0.560	.18997				.00000	31.85
  78	25-Oct	0.810	0.820	0.560	.19472				.00000	32.22
  79	26-Oct	0.800	0.610	0.600	.20354				.00000	30.64
  80	27-Oct	0.820	0.840	0.630	.22717				.00000	30.44	20
  81	28-Oct	0.860	0.840	0.630	.23825				.00000	31.15
  82	29-Oct	0.900	0.850	0.630	.25230				.00000	31.81
  83	30-Oct	0.960	0.850	0.630	.26912				.00000	32.23	25
  84	31-Oct	0.940	0.880	0.650	.28148				.00000	32.04
  85	1-Nov	0.940	0.870	0.680	.29112				.00000	33.04
  86	2-Nov	0.960	0.930	0.700	.32717				.00000	34.56
  87	3-Nov	0.950	0.960	0.680	.32465				.00000	34.58
  88	4-Nov	0.960	0.980	0.680	.33491				.00000	35.50
  89	5-Nov	0.970	1.000	0.680	.34530				.00000	36.50
  90	6-Nov	0.980	1.020	0.680	.35584				.00000	37.17
  91	7-Nov	0.980	1.090	0.720	.40263				.00000	36.89
  92	8-Nov	0.980	1.060	0.780	.42417				.00000	37.18	32
  93	9-Nov	0.980	1.070	0.800	.43915				.00000	34.57
  94	10-Nov	1.030	1.070	0.660	.38079				.00000	34.95
  95	11-Nov	1.040	1.090	0.670	.39760				.00000	34.36
  96	12-Nov	1.050	1.110	0.670	.40879				.00000	33.78
  97	13-Nov	1.060	1.130	0.680	.42639				.00000	33.19	25

  98

  14-Nov

  Died Nov. 14 1995

  #VALUE!

  Died Nov. 14 1995

  #VALUE!

  99

  T-1 AVERAGE GROWTH

  T-2 AVERAGE GROWTH

  100		0.486	0.505	0.380	0.112	0.026	0.026	0.026	0.000

• [0189]

  DAY	DATE	X	Y	Z		X	Y	Z		X	Y	Z

  DOB 11/26/94	A-488 LT SIDE T-1	EVOL	A-488 LT NECK T-2	EVOL	A-488 LT BOTTOM T-3	EVOL

  1	7/20/95	0 050	0 050	0 050	.00007				.00000				.00000
  2	7/21/95	0.050	0.050	0.050	.00007	0.050	0.050	0.050	.00007				.00000
  3	7/22/95	0.060	0.060	0.060	.00011	0.060	0.060	0.060	.00011				.00000
  4	7/23/95	0.070	0.070	0.070	.00018	0.070	0.070	0.070	.00018				.00000
  5	7/24/95	0.070	0.070	0.070	.00018	0.070	0.070	0.070	.00018				.00000
  6	7/26/95	0.070	0.070	0.070	.00018	0.080	0.080	0.080	.00027				.00000
  7	7/26/95	0.070	0.070	0.070	.00018	0.080	0.080	0.080	.00027				.00000
  8	7/27/95	0.070	0.070	0.070	.00018	0.100	0.100	0.100	.00052	0.070	0.070	0.070	.00018
  9	7/28/95	0.070	0.070	0.050	.00013	0.100	0.100	0.070	.00037	0.070	0.070	0.070	.00018
  10	7/29/95	0.070	0.070	0.050	.00013	0.100	0.100	0.070	.00037	0.070	0.070	0.070	.00018
  11	7/30/95	0.070	0.070	0.050	.00013	0.100	0.100	0.070	.00037	0.070	0.070	0.070	.00018
  12	7/31/95	0.070	0.070	0.050	.00013	0.100	0.100	0.070	.00037	0.070	0.070	0.070	.00018
  13	8/1/95	0.070	0.070	0.050	.00013	0.100	0.100	0.070	.00037	0.070	0.070	0.070	.00018
  14	8/2/95	0.070	0.070	0.050	.00013	0.100	0.100	0.070	.00037	0.070	0.070	0.070	.00018
  15	8/2/95	0.070	0.070	0.050	.00013	0.100	0.100	0.070	.00037	0.070	0.070	0.070	.00018
  16	8/4/95	0.070	0.070	0.050	.00013	0.100	0.100	0.050	.00026	0.070	0.070	0.070	.00018
  17	8/5/95	0.070	0.070	0.050	.00013	0.100	0.100	0.050	.00026	0.070	0.070	0.070	.00018
  18	8/6/95	0.070	0.070	0.050	.00013	0.100	0.100	0.050	.00026	0.070	0.070	0.070	.00018
  19	8/7/95	0.070	0.070	0.050	.00013	0.130	0.130	0.070	.00062	0.120	0.120	0.070	.00053
  20	8/8/95	0.070	0.070	0.050	.00013	0.130	0.130	0.070	.00062	0.100	0.100	0.070	.00037
  21	8/9/95	0.070	0.070	0.050	.00013	0.130	0.130	0.070	.00062	0.100	0.100	0.070	.00037
  22	8/10/95	0.070	0.070	0.050	.00013	0.130	0.130	0.070	.00062	0.100	0.100	0.070	.00037
  23	8/11/95	0.080	0.080	0.050	.00017	0.120	0.120	0.050	.00038	0.100	0.100	0.080	.00042
  24	8/12/95	0.080	0.080	0.050	.00017	0.110	0.110	0.050	.00032	0.100	0.100	0.080	.00042
  25	8/13/95	0.080	0.080	0.050	.00017	0.100	0.100	0.040	.00021	0.100	0.100	0.080	.00042
  26	8/14/95	0.080	0.080	0.050	.00017	0.090	0.090	0.040	.00017	0.100	0.100	0.080	.00042
  27	8/15/95	0.070	0.070	0.050	.00013	0.080	0.080	0.030	.00010	0.100	0.100	0.070	.00037
  28	8/16/95	0.070	0.070	0.050	.00013	0.070	0.070	0.030	.00008	0.100	0.100	0.070	.00037
  29	8/17/95	0.070	0.070	0.050	.00013	0.060	0.060	0.020	.00004	0.090	0.090	0.070	.00030
  30	8/18/95	0.060	0.060	0.050	.00009	0.050	0.050	0.020	.00003	0.090	0.090	0.060	.00025
  31	8/19/95	0.060	0.060	0.050	.00009	0.040	0.040	0.010	.00001	0.090	0.090	0.060	.00025
  32	8/20/95	0.060	0.050	0.050	.00009	0.020	0.020	0.010	.00000	0.090	0.090	0.060	.00025
  33	8/21/95	0.050	0.050	0.050	.00007				.00000	0.090	0.090	0.050	.00021
  34	8/22/95	0.050	0.050	0.050	.00007				.00000	0.090	0.090	0.050	.00021
  35	8/23/95	0.060	0.060	0.050	.00011				.00000	0.100	0.100	0.050	.00026
  36	8/24/95	0.060	0.060	0.050	.00011				.00000	0.100	0.100	0.000	.00026
  37	8/25/95	0.060	0.060	0.060	.00011				.00000	0.100	0.100	0.050	.00036
  38	8/26/95	0.060	0.060	0.060	.00011				.00000	0.100	0.100	0.050	.00036
  39	8/27/95	0.060	0.060	0.060	.00011				.00000	0.100	0.100	0.050	.00026
  40	8/28/95	0.060	0.060	0.060	.00011				.00000	0.100	0.100	0.050	.00026
  41	8/29/95	0.060	0.060	0.060	.00011				.00000	0.100	0.100	0.050	.00026
  42	8/30/95	0.050	0.050	0.050	.00007				.00000	0.100	0.100	0.050	.00026
  43	8/31/95	0.080	0.080	0.070	.00023				.00000	0.100	0.100	0.050	.00026
  44	9/1/95	0.110	0.110	0.090	.00057				.00000	0.100	0.100	0.050	.00026
  45	9/2/95	0.140	0.140	0.110	.00113				.00000	0.100	0.100	0.050	.00026
  46	9/3/95	0.170	0.170	0.130	.00197				.00000	0.100	0.100	0.050	.00026
  47	9/4/95	0.200	0.200	0.150	.00314				.00000	0.100	0.100	0.050	.00026
  48	9/5/95	0.230	0.230	0.170	.00471				.00000	0.100	0.100	0.050	.00026
  49	9/6/95	0.290	0.290	0.190	.00837				.00000	0.100	0.100	0.050	.00026
  50	9/7/95	0.320	0.320	0.210	.01126				.0000	0.100	0.100	0.050	.00026
  51	9/8/95	0.350	0.350	0.230	.01475				.0000	0.100	0.100	0.050	.00026
  52	9/9/95	0.380	0.380	0.250	.01890				.0000	0.100	0.100	0.050	.00026
  53	9/10/95	0.410	0.390	0.260	.02176				.0000	0.100	0.100	0.050	.00026
  54	9/11/95	0.440	0.400	0.270	.02488				.0000	0.100	0.100	0.050	.00026
  55	9/12/95	0.460	0.410	0.280	.02764				.0000	0.100	0.100	0.050	.00026
  56	9/13/95	0.470	0.410	0.280	.02825				.0000	0.100	0.100	0.070	.00037
  57	9/14/95	0.500	0.470	0.270	.03322				.0000	0.100	0.100	0.070	.00037
  58	9/15/95	0.510	0.460	0.330	.04053				.0000	0.100	0.100	0.070	.00037
  59	9/16/95	0.510	0.420	0.400	.04485				.0000	0.100	0.100	0.100	.00052
  60	9/17/95	0.510	0.460	0.350	.04298				.0000	0.100	0.100	0.100	.00052
  61	9/18/95	0.540	0.480	0.360	.04885				.0000	0.100	0.100	0.100	.00052
  62	9/19/95	0.520	0.420	0.360	.04116				.0000	0.100	0.100	0.100	.00052
  63	9/20/95	0.520	0.430	0.360	.04214				.0000	0.100	0.100	0.100	.00052
  64	9/21/95	0.520	0.450	0.430	.05267				.0000	0.100	0.100	0.100	.00052
  65	9/22/95	0.580	0.460	0.450	.06285				.0000	0.100	0.100	0.100	.00052
  66	9/23/95	0.580	0.470	0.450	.06422				.0000	0.100	0.100	0.100	.00052
  67	9/24/95	0.585	0.500	0.465	.07120				.0000	0.100	0.100	0.100	.00052
  68	9/25/95	0.590	0.520	0.480	.07709				.0000	0.100	0.100	0.100	.00052
  69	9/26/95	0.590	0.520	0.480	.07709				.0000	0.100	0.100	0.100	.00052
  70	9/27/95	0.590	0.520	0.480	.07709				.0000	0.100	0.100	0.100	.00052
  71	9/28/95	0.650	0.550	0.490	.09170				.0000	0.120	0.100	0.100	.00063
  72	9/29/95	0.660	0.560	0.450	.08707				.0000	0.100	0.100	0.100	.00052
  73	9/30/95	0.660	0.570	0.460	.09059				.0000	0.100	0.100	0.100	.00052
  74	10/1/95	0.070	0.570	0.470	.09396				.0000	0.100	0.100	0.100	.00052
  75	10/2/95	0.670	0.580	0.480	.09765				.0000	0.090	0.090	0.080	.00034
  76	10/3/95	0.590	0.600	0.400	.07413				.0000	0.090	0.090	0.080	.00034
  77	10/4/95	0.630	0.570	0.490	.09211				.0000	0.090	0.090	0.080	.00034
  78	10/5/95	0.690	0.580	0.490	.10266				.0000	0.090	0.090	0.080	.00034
  79	10/6/95	0.670	0.570	0.530	.10596				.0000	0.090	0.090	0.070	.00030
  80	10/7/95	0.690	0.580	0.510	.10685				.0000	0.090	0.090	0.070	.00030
  81	10/8/95	0.700	0.580	0.500	.10627				.0000	0.090	0.090	0.070	.00030
  82	10/9/95	0.710	0.590	0.480	.10626				.0000	0.090	0.090	0.070	.00030
  83	10/10/95	0.710	0.630	0.510	.11942				.0000	0.080	0.080	0.050	.00017
  84	10/11/95	0.730	0.690	0.560	.14766				.0000	0.080	0.080	0.050	.00017
  85	10/12/95	0.780	0.670	0.600	.16415				.0000	0.060	0.060	0.050	.00009
  86	10/13/95	0.810	0.710	0.600	.18064				.0000	0.060	0.060	0.050	.00009
  87	10/14/95	0.830	0.710	0.590	.18201				.0000	0.060	0.060	0.050	.00009
  88	10/15/95	0.840	0.710	0.580	.18108				.0000	0.060	0.060	0.050	.00009
  89	10/16/95	0.850	0.710	0.570	.18008				.0000	0.060	0.060	0.050	.00009
  90	10/17/95	0.850	0.720	0.550	.17621				.0000	0.100	0.100	0.050	.00026
  91	10/18/95	0.880	0.750	0.570	.19694				.0000	0.140	0.110	0.080	.00064
  92	10/19/95	0.880	0.760	0.570	.19957				.0000	0.140	0.120	0.090	.00079
  93	10/20/95	0.860	0.750	0.580	.19584				.0000	0.170	0.130	0.090	.00104
  94	10/21/95	0.850	0.740	0.590	.19426				.0000	0.170	0.130	0.090	.00104
  95	10/22/95	0.840	0.720	0.600	.18997				.0000	0.160	0.120	0.090	.00090
  96	10/23/95	0.820	0.700	0.610	.18330				.0000	0.160	0.120	0.090	.00090
  97	10/24/95	0.820	0.705	0.615	.18612				.0000	0.150	0.120	0.090	.00085
  98	10/25/95	0.820	0.710	0.620	.18896				.0000	0.140	0.120	0.090	.00079
  99	10/26/95	0.830	0.720	0.620	.19396				.0000	0.160	0.130	0.100	.00109
  100	10/27/95	0.850	0.740	0.610	.20086				.0000	0.190	0.140	0.100	.00139
  101	10/28/95	0.890	0.750	0.640	.22364				.00000	0.190	0.150	0.110	.00164
  102	10/29/95	0.930	0.750	0.680	.24830				.00000	0.190	0.150	0.120	.00179
  103	10/30/95	0.970	0.760	0.710	.27401				.00000	0.190	0.160	0.130	.00207
  104	11/31/95	0.970	0.750	0.780	.29706				.00000	0.230	0.190	0.140	.00320
  105	11/1/95	0.970	0.780	0.820	.32479				.00000	0.230	0.250	0.140	.00421
  106	11/2/95	0.970	0.830	0.850	.35825				.00000	0.230	0.250	0.160	.00482
  107	11/3/95	0.970	0.860	0.790	.34500				.00000	0.240	0.250	0.170	.00534
  108	11/4/95	0.970	0.880	0.770	.34408				.00000	0.240	0.250	0.170	.00534
  109	11/5/95	0.960	0.910	0.760	.34757				.00000	0.240	0.250	0.170	.00534
  110	11/6/95	0.960	0.930	0.740	.34586				.00000	0.240	0.250	0.170	.00534
  111	11/7/95	0.960	0.940	0.760	.35903				.00000	0.240	0.250	0.170	.00534
  112	11/8/95	1.020	0.900	0.790	.37965				.00000	0.260	0.250	0.200	.00661
  113	11/9/95	1.050	0.940	0.800	.41336				.00000	0.260	0.280	0.200	.00762
  114	11/10/95	1.080	0.960	0.770	.41793				.00000	0.250	0.280	0.200	.00733
  115	11/11/95	1.080	0.960	0.770	.41793				.00000	0.250	0.280	0.200	.00733
  116	11/12/95	1.080	0.960	0.770	.41793				.00000	0.250	0.280	0.200	.00733

  117	11/13/95	DIED 11/13/95	#VAL-	DIED 11/13/95	#VAL-	DIED 11/13/95
  			UE!		UE!

  DAY

  DATE

  X

  Y

  Z

  	DOB 11/26/94	A-488 LT ARM T-4	EVOL	WEIGHT GRAMS	HEMOTOCRIT

  	1	7/20/95				.00000	36.58
  	2	7/21/95				.00000	35.98
  	3	7/22/95				.00000	35.26
  	4	7/23/95				.00000	35.73	45
  	5	7/24/95				.00000	35.56
  	6	7/26/95				.00000	35.39
  	7	7/26/95				.00000	35.22
  	8	7/27/95				.00000	35.05
  	9	7/28/95				.00000	35.38
  	10	7/29/95				.00000	35.18
  	11	7/30/95				.00000	34.98
  	12	7/31/95				.00000	34.79
  	13	8/1/95				.00000	34.56
  	14	8/2/95				.00000	34.38
  	15	8/2/95				.00000	35.18
  	16	8/4/95				.00000	35.31	46
  	17	8/5/95				.00000	32.00
  	18	8/6/95				.00000	34.70
  	19	8/7/95				.00000	35.35
  	20	8/8/95				.00000	35.27
  	21	8/9/95				.00000	34.54
  	22	8/10/95				.00000	35.11
  	23	8/11/95				.00000	35.40
  	24	8/12/95				.00000	35.30
  	25	8/13/95				.00003	25.20
  	26	8/14/95				.00000	35.10
  	27	8/15/95				.00000	25.00
  	28	8/16/95				.00000	34.60
  	29	8/17/95				.00000	34.80
  	30	8/18/95				.00000	24.70
  	31	8/19/95				.00000	34.60
  	32	8/20/95				.00000	34.50
  	33	8/21/95				.00000	34.44
  	34	8/22/95				.00000	36.30
  	35	8/23/95				.00000	35.11
  	36	8/24/95				.00000	25.20
  	37	8/25/95				.00000	35.41
  	38	8/26/95				.00000	35.48
  	39	8/27/95				.00000	32.02
  	40	8/28/95				.00000	32.36
  	41	8/29/95				.00000	30.80
  	42	8/30/95				.00000	20.24
  	43	8/31/95				.00000	20.56
  	44	9/1/95				.00000	29.87
  	45	9/2/95				.00000	30.19
  	46	9/3/95				.00000	30.51
  	47	9/4/95				.00000	30.82
  	48	9/5/95				.00000	31.14
  	49	9/6/95				.00000	21.45
  	50	9/7/95				.00000	31.77
  	51	9/8/95				.00000	32.09
  	52	9/9/95				.00000	32.48
  	53	9/10/95				.00000	32.72
  	54	9/11/95				.00000	33.04
  	55	9/12/95				.00000	33.35
  	56	9/13/95				.00000	33.67
  	57	9/14/95				.00000	34.14
  	58	9/15/95				.00000	33.44
  	59	9/16/95				.00000	33.44
  	60	9/17/95				.00000	34.25
  	61	9/18/95				.00000	33.88
  	62	9/19/95				.00000	34.26
  	63	9/20/95				.00000	34.20
  	64	9/21/95				.00000	32.84
  	65	9/22/95				.00000	33.55
  	66	9/23/95				.00000	34.15
  	67	9/24/95				.00000	33.03
  	68	9/25/95				.00000	31.90
  	69	9/26/95				.00000	31.81
  	70	9/27/95				.00000	31.85
  	71	9/28/95				.00000	31.12
  	72	9/29/95				.00000	31.58
  	73	9/30/95				.00000	31.06
  	74	10/1/95				.00000	30.55
  	75	10/2/95				.00000	30.03	40
  	76	10/3/95				.00000	30.51
  	77	10/4/95				.00000	31.19
  	78	10/5/95				.00000	30.82
  	79	10/6/95				.00000	30.83
  	80	10/7/95				.00000	31.25
  	81	10/8/95				.00000	31.67
  	82	10/9/95				.00000	32.09
  	83	10/10/95				.00000	31.69	40
  	84	10/11/95				.00000	32.70
  	85	10/12/95				.00000	32.08
  	86	10/13/95				.00000	32.84
  	87	10/14/95				.00000	33.15
  	88	10/15/95				.00000	33.45
  	89	10/16/95				.00000	33.77
  	90	10/17/95				.00000	32.41
  	91	10/18/95				.00000	32.50
  	92	10/19/95				.00000	31.93
  	93	10/20/95				.00000	32.32
  	94	10/21/95				.00000	32.50
  	95	10/22/95				.00000	32.70
  	96	10/23/95				.00000	32.95
  	97	10/24/95				.00000	33.15
  	98	10/25/95				.00000	33.26
  	99	10/26/95				.00000	33.63
  	100	10/27/95				.00000	35.44	40
  	101	10/28/95				.00000	35.84
  	102	10/29/95				.00000	35.23
  	103	10/30/95				.00000	36.63	37
  	104	11/31/95				.00000	34.66
  	105	11/1/95				.00000	35.78
  	106	11/2/95				.00000	34.56
  	107	11/3/95				.00000	34.43
  	108	11/4/95				.00000	34.14
  	109	11/5/95				.00000	33.85
  	110	11/6/95				.00000	33.56
  	111	11/7/95	0.380	0.310	0.200	.01233	35.30
  	112	11/8/95	0.400	0.320	0.200	.01340	34.68	30
  	113	11/9/95	0.400	0.330	0.210	.01451	33.71
  	114	11/10/95	0.400	0.310	0.230	.01493	33.49
  	115	11/11/95	0.400	0.310	0.230	.01493	33.39
  	116	11/12/95	0.400	0.310	0.230	.01493	33.29

  	117	11/13/95	DIED 11/13/95	#VAL-	33 19
  				UE!

• [0190]

  DAY	DATE	X	Y	Z	EVOL	X	Y	Z	EVOL	X	Y	Z	EVOL	X	Y	Z

  							A-490 RT
  DOB 12/19/94	A-490 RT SIDE T-1		A-490 LT SIDE T-2		A-490 LT SIDE T-3		THIGH T-4
  1	10/11/95	0.150	0.150	0.120	.00141	0.150	0.150	0.150	.00177	0.100	0.100	0.100	.00052
  2	10/12/95	0.150	0.100	0.120	.00094	0.150	0.150	0.150	.00177	0.100	0.100	0.100	.00052
  3	10/13/95	0.150	0.100	0.120	.00094	0.150	0.150	0.150	.00177	0.100	0.100	0.100	.00052
  4	10/14/95	0.150	0.110	0.120	.00104	0.170	0.170	0.150	.00227	0.100	0.100	0.100	.00052
  5	10/15/95	0.160	0.110	0.120	.00111	0.190	0.180	0.150	.00269	0.100	0.100	0.100	.00052
  6	10/16/95	0.160	0.120	0.120	.00121	0.200	0.200	0.150	.00314	0.100	0.100	0.100	.00052
  7	10/17/95	0.180	0.160	0.120	.00181	0.200	0.250	0.200	.00524	0.150	0.150	0.150	.00177
  8	10/18/95	0.230	0.200	0.130	.00313	0.240	0.270	0.210	.00712	0.180	0.180	0.160	.00271
  9	10/19/95	0.260	0.240	0.150	.00490	0.270	0.270	0.210	.00801	0.220	0.220	0.160	.00405
  10	10/20/95	0.300	0.250	0.150	.00589	0.300	0.310	0.230	.01120	0.230	0.220	0.160	.00424
  11	10/21/95	0.310	0.260	0.150	.00633	0.320	0.330	0.230	.01271	0.230	0.230	0.160	.00443
  12	10/22/95	0.320	0.260	0.150	.00653	0.330	0.350	0.230	.01391	0.240	0.240	0.160	.00482
  13	10/23/95	0.330	0.270	0.160	.00746	0.340	0.370	0.230	.01515	0.240	0.250	0.160	.00503
  14	10/24/95	0.350	0.285	0.160	.00836	0.350	0.385	0.230	.01622	0.260	0.250	0.160	.00544
  15	10/25/95	0.360	0.300	0.160	.00905	0.360	0.400	0.230	.01734	0.270	0.250	0.160	.00565
  16	10/26/95	0.410	0.340	0.220	.01605	0.400	0.410	0.250	.02146	0.270	0.250	0.200	.00707
  17	10/27/95	0.460	0.360	0.240	.02081	0.440	0.410	0.250	.02361	0.270	0.270	0.220	.00840
  18	10/28/95	0.490	0.400	0.260	.02668	0.465	0.430	0.270	.02826	0.280	0.290	0.220	.00935
  19	10/29/95	0.520	0.460	0.280	.03506	0.490	0.450	0.280	.03232	0.290	0.310	0.220	.01035
  20	10/30/95	0.540	0.540	0.300	.04580	0.510	0.460	0.300	.03684	0.300	0.330	0.210	.01088
  21	10/31/95	0.530	0.390	0.360	.03895	0.500	0.480	0.300	.03769	0.280	0.320	0.200	.00938
  22	11/1/95	0.510	0.450	0.400	.04806	0.480	0.480	0.370	.04463	0.280	0.400	0.200	.01173
  23	11/2/95	0.560	0.470	0.410	.05649	0.520	0.470	0.340	.04350	0.320	0.420	0.220	.01548
  24	11/3/95	0.520	0.500	0.440	.05989	0.540	0.460	0.380	.04941	0.330	0.380	0.240	.01576
  25	11/4/95	0.560	0.510	0.430	.06429	0.560	0.470	0.390	.05374	0.350	0.400	0.300	.02199
  26	11/5/95	0.620	0.510	0.420	.06952	0.580	0.480	0.400	.05830	0.370	0.420	0.340	.02766
  27	11/6/95	0.680	0.520	0.410	.07589	0.600	0.490	0.410	.06310	0.380	0.430	0.360	.03079
  28	11/7/95	0.680	0.530	0.400	.07547	0.660	0.520	0.410	.07366	0.380	0.460	0.330	.03020
  29	11/8/95	0.680	0.580	0.440	.09085	0.540	0.670	0.440	.08334	0.430	0.500	0.360	.04277	0.190	0.240	0.180
  30	11/9/95	0.700	0.610	0.440	.09836	0.550	0.670	0.380	.07331	0.460	0.510	0.400	.04913	0.200	0.270	0.200
  31	11/10/95	0.730	0.630	0.430	.10353	1.070	0.640	0.410	.14698				.00000	0.220	0.260	0.200
  32	11/11/95	0.730	0.640	0.430	.10517	1.040	0.660	0.490	.17607				.00000	0.250	0.250	0.220
  33	11/12/95	0.740	0.640	0.430	.10661	0.990	0.680	0.550	.19383				.00000	0.290	0.240	0.240
  34	11/13/95	0.740	0.650	0.430	.10828	0.950	0.690	0.620	.21276				.00000	0.330	0.220	0.260
  35	11/14/95	0.740	0.680	0.450	.11854	1.000	0.720	0.570	.21484				.00000	0.300	0.220	0.240
  36	11/15/95	0.760	0.700	0.470	.13090	1.000	0.740	0.630	.24408				.00000	0.300	0.200	0.240
  37	11/16/95	0.780	0.690	0.470	.13242	1.000	0.760	0.630	.25065				.00000	0.310	0.240	0.230
  38	11/17/95	0.800	0.720	0.470	.14172	1.060	0.790	0.630	.27618				.00000	0.350	0.280	0.230
  39	11/18/95	0.830	0.720	0.460	.14391	1.070	0.810	0.640	.29038				.00000	0.380	0.300	0.240
  40	11/19/95	0.860	0.720	0.460	.14911	1.080	0.830	0.650	.30502				.00000	0.410	0.310	0.240
  41	11/20/95	0.890	0.720	0.450	.15096	1.090	0.850	0.660	.32012				.00000	0.450	0.320	0.250
  42	11/21/95	0.860	0.700	0.480	.15127	1.090	0.900	0.690	.35435				.00000	0.450	0.300	0.250
  43	11/22/95	0.860	0.730	0.480	.15775	1.080	0.960	0.690	.37451				.00000	0.470	0.320	0.270
  44	11/23/95	0.850	0.780	0.510	.17701	1.080	0.950	0.690	.37061				.00000	0.485	0.330	0.270
  45	11/24/95	0.850	0.850	0.550	.20803	1.080	0.950	0.690	.37061				.00000	0.500	0.350	0.270
  46	11/25/95	0.850	0.850	0.550	.20803	1.080	0.980	0.710	.39339				.00000	0.510	0.350	0.280
  47	11/26/95	0.850	0.850	0.550	.20803	1.080	1.050	0.730	.43336				.00000	0.510	0.350	0.290
  48	11/27/95	0.850	0.850	0.550	.20803	1.090	1.090	0.750	.46648				.00000	0.520	0.350	0.310
  49	11/28/95	0.850	0.850	0.550	.20803	1.090	1.100	0.750	.47076				.00000	0.520	0.350	0.310

  50	11/29/95	Died 11/29/95	#VAL-	Died 11/29/95	#VAL-	Died 11/29/95	#VAL-	Died 11/29/95
  			UE!		UE!		UE!

  DOB 12/19/94

  WEIGHT

  	DAY	DATE	EVOL	GRAMS
  	1	10/11/95	.00000	29.11	44
  	2	10/12/95	.00000	28.19
  	3	10/13/95	.00000	29.77
  	4	10/14/95	.00000	29.90
  	5	10/15/95	.00000	30.20
  	6	10/16/95	.00000	30.49
  	7	10/17/95	.00000	30.24
  	8	10/18/95	.00000	30.69
  	9	10/19/95	.00000	30.01
  	10	10/20/95	.00000	30.47
  	11	10/21/95	.00000	30.90
  	12	10/22/95	.00000	31.30
  	13	10/23/95	.00000	31.52
  	14	10/24/95	.00000	30.50
  	15	10/25/95	.00000	29.74
  	16	10/26/95	.00000	29.14
  	17	10/27/95	.00000	29.83	40
  	18	10/28/95	.00000	30.30
  	19	10/29/95	.00000	30.90
  	20	10/30/95	.00000	31.14	34
  	21	10/31/95	.00000	30.33
  	22	11/1/95	.00000	32.44
  	23	11/2/95	.00000	31.61
  	24	11/3/95	.00000	32.21
  	25	11/4/95	.00000	32.70
  	26	11/5/95	.00000	33.20
  	27	11/6/95	.00000	33.59
  	28	11/7/95	.00000	33.16
  	29	11/8/95	.00430	34.41	30
  	30	11/9/95	.00565	35.11
  	31	11/10/95	.00599	34.92
  	32	11/11/95	.00720	35.80
  	33	11/12/95	.00874	36.80
  	34	11/13/95	.00988	37.66
  	35	11/14/95	.00829	39.12
  	36	11/15/95	.00754	38.97	32
  	37	11/16/95	.00896	39.02
  	38	11/17/95	.01180	40.48
  	39	11/18/95	.01432	41.50
  	40	11/19/95	.01597	42.50
  	41	11/20/95	.01885	43.50	27
  	42	11/21/95	.01767	43.88
  	43	11/22/95	.02126	44.12
  	44	11/23/95	.02262	45.50
  	45	11/24/95	.02474	46.96
  	46	11/25/95	.02616	46.66
  	47	11/26/95	.02710	46.36
  	48	11/27/95	.02954	46.06
  	49	11/28/95	.02954	39.35
  	50	11/29/95	#VAL-	39.88
  			UE!

  	T-1 AVERAGE GROWTH	T-2 AVERAGE GROWTH	T-3 AVERAGE GROWTH

  	0.560	0.491	0.340	0.078	0.644	0.560	0.413	0.137	0.254	0.276	0.202	0.011

• [0191]

  DAY	DATE	X	Y	Z	EVOL	X	Y	Z	EVOL	X	Y	Z	EVOL	X	Y	Z	EVOL

  	A-492 RT ABDO-		A-492 LT ABDO
  	MEN T-1		MEN T-2		A-492 RT ARM T-3		A-492 LT ARM T-4
  	1	15-Sep	0.030	0.030	0.030	.00001				.00000				.00000				.00000
  	2	16-Sep	0.030	0.030	0.030	.00001				.00000				.00000				.00000
  	3	17-Sep	0.050	0.050	0.050	.00007				.00000				.00000				.00000
  	4	18-Sep	0.100	0.100	0.100	.00052				.00000				.00000				.00000
  	5	19-Sep	0.050	0.050	0.050	.00007				.00000				.00000				.00000
  	6	20-Sep	0.050	0.050	0.050	.00007				.00000				.00000				.00000
  	7	21-Sep	0.050	0.050	0.050	.00007				.00000				.00000				.00000
  	8	22-Sep	0.050	0.050	0.050	.00007				.00000				.00000				.00000
  	9	23-Sep	0.050	0.050	0.050	.00007				.00000				.00000				.00000
  	10	24-Sep	0.030	0.030	0.030	.00001				.00000				.00000				.00000
  	11	25-Sep	0.030	0.030	0.030	.00001				.00000				.00000				.00000
  	12	26-Sep	0.030	0.030	0.030	.00001				.00000				.00000				.00000
  	13	27-Sep	0.030	0.030	0.030	.00001				.00000				.00000				.00000
  	14	28-Sep	0.030	0.030	0.030	.00001				.00000				.00000				.00000
  	15	29-Sep	0.030	0.030	0.030	.00001				.00000				.00000				.00000
  	16	30-Sep	0.030	0.030	0.030	.00001				.00000				.00000				.00000
  	17	1-Oct				.00000				.00000				.00000				.00000
  	18	2-Oct				.00000	0.050	0.050	0.050	.00007				.00000				.00000
  	19	3-Oct				.00000	0.050	0.050	0.050	.00007				.00000				.00000
  	20	4-Oct				.00000	0.050	0.050	0.050	.00007				.00000				.00000
  	21	5-Oct				.00000	0.030	0.030	0.030	.00001				.00000				.00000
  	22	6-Oct				.00000	0.030	0.030	0.030	.00001				.00000				.00000
  	23	7-Oct				.00000	0.040	0.040	0.040	.00003				.00000				.00000
  	24	8-Oct				.00000	0.040	0.040	0.040	.00003				.00000				.00000
  	25	9-Oct				.00000	0.050	0.050	0.050	.00007				.00000				.00000
  	26	10-Oct				.00000	0.050	0.050	0.050	.00007				.00000				.00000
  	27	11-Oct				.00000	0.050	0.050	0.050	.00007	0.100	0.100	0.100	.00052				.00000
  	28	12-Oct				.00000	0.050	0.050	0.050	.00007	0.100	0.100	0.110	.00058	0.090	0.090	0.070	.00030
  	29	13-Oct				.00000	0.050	0.050	0.050	.00007	0.100	0.100	0.100	.00052	0.090	0.090	0.060	.00025
  	30	14-Oct				.00000	0.040	0.040	0.040	.00003	0.100	0.100	0.100	.00052	0.090	0.090	0.070	.00030
  	31	15-Oct				.00000	0.040	0.040	0.040	.00003	0.100	0.100	0.100	.00052	0.090	0.090	0.080	.00034
  	32	16-Oct				.00000	0.030	0.030	0.030	.00001	0.100	0.100	0.100	.00052	0.100	0.100	0.090	.00047
  	33	17-Oct				.00000	0.030	0.030	0.030	.00001	0.150	0.150	0.150	.00177	0.120	0.120	0.110	.00083
  	34	18-Oct				.00000	0.030	0.030	0.030	.00001	0.200	0.180	0.150	.00263	0.180	0.180	0.160	.00271
  	35	19-Oct				.00000	0.030	0.030	0.030	.00001	0.240	0.200	0.150	.00377	0.210	0.200	0.160	.00352
  	36	20-Oct				.00000	0.030	0.030	0.030	.00001	0.270	0.240	0.200	.00578	0.240	0.210	0.170	.00449
  	37	21-Oct				.00000	0.030	0.030	0.030	.00001	0.270	0.240	0.200	.00678	0.260	0.240	0.170	.00555
  	38	22-Oct				.00000	0.030	0.030	0.030	.00001	0.270	0.240	0.200	.00678	0.280	0.270	0.170	.00673
  	39	23-Oct				.00000	0.030	0.030	0.030	.00001	0.270	0.240	0.200	.00678	0.290	0.290	0.170	.00748
  	40	24-Oct				.00000				.00000	0.280	0.270	0.200	.00792	0.290	0.290	0.170	.00748
  	41	25-Oct				.00000				.00000	0.300	0.300	0.200	.00942	0.290	0.300	0.180	.00820
  	42	26-Oct				.00000				.00000	0.350	0.300	0.220	.01209	0.290	0.290	0.190	.00837
  	43	27-Oct				.00000				.00000	0.340	0.300	0.240	.01282	0.290	0.280	0.200	.00850
  	44	28-Oct				.00000				.00000	0.350	0.300	0.250	.01374	0.310	0.310	0.230	.01157
  	45	29-Oct				.00000				.00000	0.350	0.300	0.250	.01374	0.330	0.340	0.250	.01468
  	46	30-Oct				.00000				.00000	0.360	0.300	0.260	.01470	0.340	0.370	0.280	.01844
  	47	31-Oct				.00000				.00000	0.340	0.320	0.270	.01538	0.320	0.360	0.270	.01719
  	48	1-Nov				.00000				.00000	0.350	0.280	0.260	.01334	0.330	0.400	0.270	.01866
  	49	2-Nov				.00000				.00000	0.360	0.300	0.280	.01583	0.350	0.400	0.270	.01979
  	50	3-Nov				.00000				.00000	0.400	0.360	0.310	.02337	0.370	0.440	0.260	.02216
  	51	4-Nov				.00000				.00000	0.420	0.340	0.290	.02168	0.355	0.450	0.270	.02258
  	52	5-Nov				.00000				.00000	0.440	0.320	0.270	.01990	0.340	0.450	0.290	.02323
  	53	6-Nov				.00000				.00000	0.450	0.300	0.250	.01767	0.330	0.460	0.300	.02384
  	54	7-Nov				.00000				.00000	0.410	0.360	0.290	.02241	0.380	0.480	0.320	.03056
  	55	8-Nov				.00000				.00000	0.460	0.350	0.300	.02529	0.420	0.530	0.360	.04195
  	56	9-Nov				.00000				.00000	0.440	0.340	0.290	.02271	0.410	0.450	0.360	.03786
  	57	10-Nov				.00000				.00000	0.470	0.350	0.320	.02756	0.490	0.500	0.380	.04277
  	58	11-Nov				.00000				.00000	0.430	0.340	0.320	.02449	0.450	0.490	0.380	.04386
  	59	12-Nov				.00000				.00000	0.390	0.320	0.320	.02091	0.460	0.490	0.390	.04602
  	60	13-Nov				.00000				.00000	0.350	0.310	0.320	.01818	0.470	0.480	0.390	.04606
  	61	14-Nov				.00000				.00000	0.390	0.310	0.300	.01899	0.480	0.500	0.360	.04523
  	62	15-Nov				.00000				.00000	0.380	0.340	0.300	.02029	0.460	0.540	0.380	.04941
  	63	16-Nov				.00000				.00000	0.380	0.340	0.290	.01961	0.470	0.510	0.370	.04643
  	64	17-Nov				.00000				.00000	0.400	0.350	0.300	.02199	0.460	0.530	0.370	.04722
  	65	18-Nov				.00000				.00000	0.400	0.380	0.320	0.2546	0.480	0.530	0.350	.04661
  	66	19-Nov				.00000				.00000	0.410	0.410	0.340	.02992	0.490	0.530	0.330	.04486
  	67	20-Nov				.00000				.00000	0.410	0.440	0.360	.03400	0.500	0.530	0.310	.04301
  	68	21-Nov				.00000				.00000	0.430	0.430	0.330	.03194	0.500	0.430	0.320	.03602
  	69	22-Nov				.00000				.00000	0.420	0.440	0.330	.03193	0.520	0.540	0.420	.06174
  	70	23-Nov				.00000				.00000	0.440	0.470	0.370	.04006	0.520	0.520	0.410	.05804
  	71	24-Nov				.00000				.00000	0.450	0.500	0.400	.04712	0.520	0.500	0.400	.05444
  	72	25-Nov				.00000				.00000	0.470	0.500	0.390	.04798	0.530	0.510	0.390	.05519
  	73	26-Nov				.00000				.00000	0.500	0.500	0.380	.04973	0.540	0.520	0.390	.05733
  	74	27-Nov				.00000				.00000	0.520	0.500	0.370	.05036	0.550	0.530	0.380	.05799
  	75	28-Nov				.00000				.00000	0.550	0.500	0.370	.05327	0.600	0.540	0.380	.06445
  	76	29-Nov				.00000				.00000	0.570	0.490	0.370	.05410	0.640	0.610	0.380	.07766
  	77	30-Nov				.00000				.00000	0.570	0.480	0.370	.05299	0.640	0.610	0.380	.07766
  	78	1-Dec				.00000				.00000	0.560	0.460	0.390	.05259	0.500	0.660	0.370	.06392
  	79	2-Dec				.00000				.00000	0.540	0.450	0.390	.04961	0.520	0.650	0.390	.06901
  	80	3-Dec				.00000				.00000	0.520	0.450	0.390	.04777	0.530	0.560	0.410	.07280
  	81	4-Dec				.00000				.00000	0.500	0.450	0.390	.04594	0.540	0.630	0.430	.07658
  	82	5-Dec				.00000				.00000	0.660	0.470	0.390	.06333	0.570	0.650	0.430	.08340
  	83	6-Dec				.00000				.00000	0.680	0.510	0.410	.07444	0.600	0.650	0.430	.08779
  	84	7-Dec				.00000				.00000	0.590	0.510	0.430	.06773	0.630	0.690	0.430	.09785
  	85	8-Dec				.00000				.00000	0.730	0.540	0.400	.08255	0.660	0.720	0.430	.10697
  	86	9-Dec				.00000				.00000	0.740	0.540	0.400	.06368	0.690	0.730	0.430	.11339
  	87	10-Dec				.00000				.00000	0.740	0.540	0.400	.06366	0.720	0.740	0.430	.11994
  	88	11-Dec				.00000				.00000	0.750	0.540	0.400	.06481	0.750	0.750	0.440	.12957
  	89	12-Dec				.00000				.00000	0.770	0.550	0.410	.09090	0.750	0.770	0.440	.13302
  	90	13-Dec				.00000				.00000	0.790	0.560	0.420	.09727	0.750	0.790	0.440	.13648
  	91	14-Dec				.00000				.00000	0.800	0.600	0.420	.10554	0.790	0.830	0.440	.15103
  	92	15-Dec				.00000				.00000	0.810	0.630	0.400	.10686	0.800	0.810	0.480	.16283
  	93	16-Dec				.00000				.00000	0.800	0.650	0.390	.10617	0.800	0.790	0.490	.16212
  	94	17-Dec				.00000				.00000	0.800	0.670	0.370	.10382	0.800	0.760	0.510	.16233
  	95	18-Dec				.00000				.00000	0.790	0.690	0.350	.09988	0.800	0.730	0.520	.15898
  	96	19-Dec				.00000				.00000	0.810	0.650	0.350	.09647	0.780	0.720	0.510	.14994
  	97	20-Dec				.00000				.00000	0.830	0.610	0.350	.09277	0.760	0.720	0.490	.14037
  	98	21-Dec				.00000				.00000	0.780	0.610	0.370	.09216	0.780	0.730	0.500	.14904
  	99	22-Dec				.00000				.00000	0.590	0.510	0.370	.05828	0.720	0.720	0.490	.13298
  	100	23-Dec				.00000				.00000	0.590	0.520	0.370	.05943	0.720	0.710	0.490	.13113
  	101	24-Dec				.00000				.00000	0.590	0.530	0.370	.06057	0.720	0.710	0.480	.12845
  	102	25-Dec				.00000				.00000	0.590	0.540	0.360	.06004	0.730	0.700	0.480	.12840
  	103	26-Dec				.00000				.00000	0.590	0.550	0.360	.06116	0.730	0.690	0.470	.12393
  	104	27-Dec				.00000				.00000	0.580	0.550	0.360	.06012	0.730	0.690	0.470	.12393

  105	28-Dec	Died 12/29/95	#VAL-	Died 12/29/95	#VAL-	Died 12/29/95	#VAL-	Died 12/29/95	VAL-
  			UE!		UE!		UE!		UE!

  			WEIGHT
  	DAY	DATE	GRAMS	H'CRIT
  	1	15-Sep	29.62
  	2	16-Sep	29.29
  	3	17-Sep	30.45
  	4	18-Sep	30.47
  	5	19-Sep	30.09
  	6	20-Sep	29.85
  	7	21-Sep	28.88
  	8	22-Sep	29.35
  	9	23-Sep	29.62
  	10	24-Sep	29.11
  	11	25-Sep	28.61
  	12	26-Sep	29.58
  	13	27-Sep	27.84
  	14	28-Sep	26.53
  	15	29-Sep	28.91
  	16	30-Sep	28.85
  	17	1-Oct	28.60
  	18	2-Oct	28.42	45
  	19	3-Oct	28.54
  	20	4-Oct	29.13
  	21	5-Oct	28.81
  	22	6-Oct	29.33
  	23	7-Oct	29.38
  	24	8-Oct	29.42
  	25	9-Oct	29.45
  	26	10-Oct	28.60	42
  	27	11-Oct	29.43
  	28	12-Oct	28.68
  	29	13-Oct	29.43
  	30	14-Oct	29.70
  	31	15-Oct	29.90
  	32	15-Oct	30.12
  	33	17-Oct	29.26
  	34	18-Oct	29.50
  	35	19-Oct	28.78
  	36	20-Oct	29.22
  	37	21-Oct	29.23
  	38	22-Oct	29.25
  	39	23-Oct	29.27
  	40	24-Oct	29.26
  	41	25-Oct	29.26
  	42	26-Oct	28.63
  	43	27-Oct	29.84	43
  	44	28-Oct	29.92
  	45	29-Oct	29.99
  	46	30-Oct	30.05	43
  	47	31-Oct	28.61
  	48	1-Nov	29.49
  	49	2-Nov	28.96
  	50	3-Nov	28.68
  	51	4-Nov	29.00
  	52	5-Nov	29.10
  	53	6-Nov	29.24
  	54	7-Nov	29.55
  	55	8-Nov	31.49	40
  	56	9-Nov	30.03
  	57	10-Nov	29.88
  	58	11-Nov	29.76
  	59	12-Nov	29.66
  	60	13-Nov	29.46
  	61	14-Nov	31.17
  	62	15-Nov	30.31	46
  	63	16-Nov	32.11
  	64	17-Nov	31.42
  	65	18-Nov	31.60
  	66	19-Nov	31.80
  	67	20-Nov	32.05	41
  	68	21-Nov	31.57
  	69	22-Nov	32.02
  	70	23-Nov	32.20
  	71	24-Nov	32.46
  	72	25-Nov	32.55
  	73	26-Nov	32.65
  	74	27-Nov	32.78
  	75	28-Nov	32.41
  	76	29-Nov	33.63	35
  	77	30-Nov	32.70
  	78	1-Dec	33.26
  	79	2-Dec	33.66
  	80	3-Dec	34.10
  	81	4-Dec	34.51
  	82	5-Dec	34.29
  	83	6-Dec	34.76	38
  	84	7-Dec	34.82
  	85	8-Dec	34.87
  	86	9-Dec	35.47
  	87	10-Dec	36.00
  	88	11-Dec	36.55
  	89	12-Dec	36.65
  	90	13-Dec	36.73	17
  	91	14-Dec	37.34
  	92	15-Dec	37.92
  	93	16-Dec	35.50
  	94	17-Dec	34.00
  	95	18-Dec	32.59
  	96	19-Dec	31.90
  	97	20-Dec	31.30	9
  	98	21-Dec	32.45
  	99	22-Dec	32.70
  	100	23-Dec	33.50
  	101	24-Dec	34.30
  	102	25-Dec	35.10
  	103	26-Dec	35.90
  	104	27-Dec	36.84

  T-1 AVERAGE GROWTH

  T-2 AVERAGE GROWTH

  T-3 AVERAGE GROWTH

  T-4 AVERAGE GROWTH

  	0.042	0.042	0.042	0.000	0.039	0.039	0.039	0.000	0.468	0.398	0.306	0.040	0.485	0.506	0.339	.06190

• [0192]

  DAY

  DATE

  X

  Y

  Z

  EVOL

  X

  Y

  Z

  EVOL

  X

  Y

  Z

  EVOL

  	A-500 RT						WEIGHT	H
  	SIDE T-1		A-500 LT LEG T-2		A-500 RT BOT T-3		GRAMS	CRIT

  1	15-Sep	0.300	0.230	0.390	.0141	0.100	0.100	0.100	.0005	0.100	0.100	0.100	.0005	34.15
  2	16-Sep	0.310	0.240	0.390	.0152	0.310	0.340	0.300	.0166	0.150	0.150	0.150	.0018	33.60
  3	17-Sep	0.280	0.310	0.330	.0150	0.330	0.250	0.300	.0130	0.150	0.150	0.100	.0012	33.44
  4	18-Sep	0.330	0.310	0.250	.0134	0.390	0.310	0.200	.0127	0.200	0.370	0.190	.0074	33.46
  5	19-Sep	0.330	0.270	0.330	.0154	0.390	0.320	0.210	.0137	0.260	0.280	0.210	.0080	34.07
  6	20-Sep	0.320	0.300	0.310	.0156	0.410	0.340	0.250	.0182	0.250	0.260	0.200	.0068	34.54
  7	21-Sep	0.360	0.350	0.370	.0244	0.340	0.340	0.300	.0182	0.310	0.310	0.260	.0131	33.02
  8	22-Sep	0.360	0.340	0.350	.0224	0.350	0.370	0.270	.0183	0.300	0.320	0.300	.0151	33.94
  9	23-Sep	0.400	0.390	0.400	.0327	0.400	0.390	0.290	.0237	0.330	0.350	0.320	.0193	34.27
  10	24-Sep	0.445	0.410	0.405	.0387	0.405	0.400	0.320	.0271	0.340	0.375	0.360	.0240	34.57
  11	25-Sep	0.490	0.430	0.410	.0452	0.410	0.410	0.360	.0317	0.350	0.400	0.400	.0293	34.74
  12	26-Sep	0.480	0.450	0.380	.0430	0.470	0.480	0.360	.0425	0.500	0.470	0.400	.0492	35.72
  13	27-Sep	0.480	0.450	0.380	.0430	0.420	0.490	0.360	.0388	0.530	0.520	0.410	.0592	35.91
  14	28-Sep	0.490	0.450	0.430	.0496	0.420	0.500	0.360	.0396	0.600	0.580	0.400	.0729	34.90
  15	29-Sep	0.530	0.450	0.410	.0512	0.430	0.530	0.290	.0346	0.660	0.590	0.450	.0917	34.38
  16	30-Sep	0.540	0.470	0.430	.0571	0.425	0.540	0.280	.0336	0.670	0.620	0.470	.1022	34.88
  17	1-Oct	0.540	0.490	0.440	.0609	0.420	0.545	0.270	.0324	0.680	0.640	0.485	.1105	35.28
  18	2-Oct	0.550	0.500	0.450	.0648	0.410	0.550	0.250	.0295	0.690	0.650	0.500	.1174	35.71	16
  19	3-Oct	0.560	0.490	0.430	.0618	0.390	0.560	0.240	.0274	0.700	0.710	0.500	.1301	34.24
  20	4-Oct	0.580	0.520	0.410	.0647	0.390	0.550	0.250	.0281	0.720	0.730	0.550	.1513	35.68
  21	5-Oct	0.530	0.450	0.390	.0487	0.390	0.530	0.280	.0303	0.600	0.840	0.540	.1900	32.73
  22	6-Oct	0.460	0.350	0.400	.0337	0.400	0.510	0.270	.0288	0.830	0.830	0.570	.2056	32.97
  23	7-Oct	0.440	0.370	0.370	.0315	0.390	0.505	0.260	.0268	0.820	0.820	0.570	.2005	33.30
  24	8-Oct	0.410	0.385	0.345	.0285	0.380	0.500	0.240	.0239	0.810	0.810	0.570	.1958	33.60
  25	9-Oct	0.390	0.400	0.320	.0261	0.370	0.490	0.210	.0199	0.800	0.800	0.570	.1910	33.80
  26	10-Oct	0.350	0.350	0.280	.0180	0.370	0.480	0.200	.0186	0.830	0.850	0.540	.1994	31.90	14

  27	11-Oct	DIED 10/11/95	#VAL-	DIED 10/11/95	#VAL-	DIED 10/11/95	#VAL-
  			UE!		UE!		UE!

• [0193]

  DAY	DATE	X	Y	Z	EVOL	X	Y	Z	EVOL	X	Y	Z	EVOL	GRAMS

  			A-538 LT		A-538 RT		WEIGHT
  	A-538 LT SIDE T-1		CHEEK T-2		ARMPIT T-3		GRAMS

  1	19-Oct	0.200	0.300	0.160	.00503				.00000				.00000	29.67
  2	20-Oct	0.200	0.340	0.190	.00676				.00000				.00000	30.24
  3	21-Oct	0.220	0.340	0.190	.00744				.00000				.00000	30.10
  4	22-Oct	0.240	0.330	0.190	.00788				.00000				.00000	30.00
  5	23-Oct	0.260	0.330	0.190	.00853				.00000				.00000	29.93
  6	24-Oct	0.250	0.350	0.200	.00916				.00000				.00000	30.12
  7	25-Oct	0.250	0.380	0.220	.01094				.00000				.00000	30.20
  8	26-Oct	0.260	0.300	0.240	.00980				.00000				.00000	29.30
  9	27-Oct	0.260	0.340	0.240	.01111				.00000				.00000	29.69	46
  10	28-Oct	0.280	0.340	0.240	.01196				.00000				.00000	29.80
  11	29-Oct	0.290	0.340	0.240	.01239				.00000				.00000	29.87
  12	30-Oct	0.300	0.340	0.240	.01262				.00000				.00000	29.93	41
  13	31-Oct	0.300	0.320	0.240	.01206				.00000				.00000	29.51
  14	1-Nov	0.310	0.300	0.230	.01120				.00000				.00000	30.26
  15	2-Nov	0.350	0.290	0.250	.01328				.00000				.00000	30.34
  16	3-Nov	0.340	0.210	0.250	.00934				.00000				.00000	30.39
  17	4-Nov	0.360	0.240	0.240	.01086				.00000				.00000	30.20
  18	5-Nov	0.380	0.270	0.240	.01289				.00000				.00000	30.10
  19	6-Nov	0.390	0.300	0.220	.01347				.00000				.00000	30.02
  20	7-Nov	0.390	0.330	0.260	.01752				.00000				.00000	29.94
  21	8-Nov	0.400	0.340	0.290	.02065				.00000				.00000	30.67	45
  22	9-Nov	0.400	0.300	0.280	.01759				.00000				.00000	28.55
  23	10-Nov	0.410	0.340	0.280	.02043				.00000				.00000	28.86
  24	11-Nov	0.430	0.360	0.300	.02431				.00000				.00000	29.20
  25	12-Nov	0.470	0.370	0.320	.02913				.00000				.00000	29.60
  26	13-Nov	0.500	0.380	0.330	.03262				.00000				.00000	29.88
  27	14-Nov	0.520	0.400	0.320	.03484				.00000				.00000	29.16
  28	15-Nov	0.540	0.420	0.320	.03799				.00000				.00000	29.41	42
  29	16-Nov	0.570	0.410	0.320	.03915				.00000				.00000	29.33
  30	17-Nov	0.600	0.410	0.320	.04121				.00000				.00000	30.45
  31	18-Nov	0.620	0.420	0.330	.04499				.00000				.00000	30.41
  32	19-Nov	0.640	0.440	0.330	.04865				.00000				.00000	30.38
  33	20-Nov	0.660	0.450	0.340	.05286				.00000				.00000	30.33	46
  34	21-Nov	0.650	0.490	0.340	.05669				.00000				.00000	30.07
  35	22-Nov	0.670	0.490	0.350	.06015	0.220	0.240	0.200	.00553				.00000	29.97
  36	23-Nov	0.685	0.510	0.360	.06584	0.220	0.240	0.200	.00553				.00000	30.50
  37	24-Nov	0.700	0.530	0.360	.06992	0.220	0.240	0.200	.00678				.00000	31.23
  38	25-Nov	0.700	0.520	0.370	.07050	0.240	0.240	0.200	.00603				.00000	31.30
  39	26-Nov	0.700	0.510	0.380	.07102	0.270	0.240	0.200	.00678				.00000	31.40
  40	27-Nov	0.700	0.500	0.390	.07146	0.290	0.250	0.200	.00759				.00000	31.56
  41	28-Nov	0.700	0.500	0.390	.07146	0.300	0.270	0.220	.00933				.00000	31.66
  42	29-Nov	0.700	0.550	0.390	.07860	0.340	0.300	0.220	.01175				.00000	32.41	41
  43	30-Nov	0.780	0.530	0.390	.08440	0.360	0.320	0.220	.01327				.00000	32.39
  44	1-Dec	0.760	0.520	0.400	.08275	0.350	0.440	0.260	.02096				.00000	32.12
  45	2-Dec	0.780	0.540	0.400	.08820	0.350	0.450	0.260	.02144				.00000	32.80
  46	3-Dec	0.800	0.560	0.400	.09381	0.360	0.460	0.260	.02254				.00000	33.20
  47	4-Dec	0.820	0.570	0.400	.09767	0.370	0.470	0.260	.02367				.00000	33.54
  48	5-Dec	0.860	0.560	0.450	.11345	0.400	0.470	0.260	.02559				.00000	33.48
  49	6-Dec	0.860	0.560	0.450	.11345	0.420	0.490	0.300	.03232	0.200	0.200	0.200	.00419	34.32	30
  50	7-Dec	0.870	0.580	0.450	.11887	0.450	0.500	0.300	.03534	0.210	0.200	0.180	.00396	34.86
  51	8-Dec	0.870	0.590	0.450	.12092	0.440	0.500	0.330	.03801	0.210	0.200	0.180	.00396	34.83
  52	9-Dec	0.890	0.600	0.470	.13139	0.500	0.540	0.330	.04664	0.210	0.210	0.190	.00439	35.50
  53	10-Dec	0.900	0.600	0.480	.13569	0.550	0.570	0.330	.05416	0.220	0.220	0.200	.00507	36.20
  54	11-Dec	0.910	0.610	0.490	.14239	0.590	0.590	0.330	.06014	0.230	0.230	0.200	.00554	36.97
  55	12-Dec	0.930	0.620	0.470	.14187	0.590	0.590	0.330	.06014	0.240	0.240	0.200	.00603	37.20
  56	13-Dec	0.950	0.630	0.460	.14412	0.590	0.590	0.330	.06014	0.250	0.250	0.210	.00687	37.43	29
  57	14-Dec	0.940	0.630	0.460	.14261	0.660	0.640	0.330	.07297	0.290	0.280	0.210	.00893	37.65
  58	15-Dec	0.930	0.620	0.460	.13885	0.660	0.640	0.340	.07518	0.290	0.270	0.210	.00851	38.15
  59	16-Dec	0.910	0.610	0.450	.13077	0.700	0.680	0.350	.08722	0.290	0.270	0.210	.00861	37.60
  60	17-Dec	0.880	0.610	0.440	.12365	0.750	0.710	0.350	.09757	0.290	0.270	0.210	.00861	36.90
  61	18-Dec	0.850	0.600	0.430	.11480	0.800	0.740	0.360	.11157	0.290	0.270	0.210	.00861	36.24
  62	19-Dec	0.870	0.590	0.430	.11555	0.780	0.740	0.360	.10878	0.310	0.300	0.220	.01071	37.20
  63	20-Dec	0.890	0.590	0.430	.11820	0.750	0.740	0.360	.10460	0.330	0.330	0.220	.01254	38.26	21
  64	21-Dec	0.930	0.620	0.470	.14187	0.760	0.780	0.360	.11172	0.330	0.330	0.230	.01311	38.65
  65	22-Dec	0.980	0.790	0.570	.23102	0.780	0.780	0.390	.12421	0.330	0.330	0.230	.01311	39.82
  66	23-Dec	1.000	0.820	0.570	.24468	0.800	0.800	0.390	.13067	0.350	0.330	0.240	.01451	40.80
  67	24-Dec	1.050	0.840	0.560	.25857	0.810	0.810	0.390	.13395	0.380	0.340	0.250	.01691	41.90
  68	25-Dec	1.100	0.860	0.560	.27733	0.820	0.820	0.440	.15488	0.410	0.340	0.260	.01897	42.80
  69	26-Dec	1.130	0.890	0.550	.28957	0.830	0.830	0.440	.15868	0.440	0.350	0.260	.02096	43.80
  70	27-Dec	1.160	0.920	0.540	.30169	0.830	0.850	0.440	.16250	0.460	0.350	0.270	.02276	44.75	27
  71	28-Dec	1.220	1.000	0.550	.35127	0.850	0.870	0.450	.17421	0.460	0.380	0.285	.02068	44.00
  72	29-Dec	1.280	1.040	0.560	.39025	0.870	0.890	0.460	.18646	0.460	0.400	0.300	.02890	43.38
  73	30-Dec	1.290	1.060	0.570	.40803	0.880	0.900	0.480	.19901	0.470	0.400	0.310	.03051	43.70
  74	31-Dec	1.290	1.070	0.580	.41910	0.880	0.920	0.490	.20767	0.470	0.400	0.310	.03051	44.00
  75	1-Jan	1.300	1.090	0.590	.43766	0.890	0.940	0.500	.21898	0.480	0.400	0.320	.03216	44.31
  76	2-Jan	1.300	1.100	0.610	.45665	0.890	0.960	0.500	.22364	0.480	0.400	0.320	.03216	45.18
  77	3-Jan	1.300	1.100	0.610	.45665	0.900	0.960	0.510	.23068	0.480	0.400	0.320	.03216	43.22	24
  78	4-Jan	1.300	1.100	0.610	.45665	0.920	0.970	0.540	.25227	0.460	0.400	0.320	.03082	44.61
  79	5-Jan	1.300	1.110	0.610	.46080	0.920	0.970	0.560	.26162	0.480	0.400	0.300	.03015	44.33
  80	6-Jan	1.280	1.150	0.620	.47777	0.930	0.980	0.570	.27196	0.480	0.400	0.300	.03015	44.70
  81	7-Jan	1.260	1.200	0.640	.50658	0.940	0.990	0.580	.28256	0.490	0.400	0.300	.03078	45.00
  82	8-Jan	1.240	1.250	0.660	.53554	0.950	0.990	0.580	.28556	0.330	0.400	0.300	.01885	45.50
  83	9-Jan	1.210	1.280	0.670	.54323	0.960	1.000	0.590	.29561	0.300	0.400	0.300	.01885	45.80
  84	10-Jan	1.190	1.300	0.680	.55070	0.970	1.000	0.590	.29960	0.310	0.400	0.300	.01947	46.20	23
  85	11-Jan	1.180	1.310	0.690	.55837	0.970	1.010	0.600	.30712	0.310	0.400	0.300	.01947	46.58
  86	12-Jan	1.200	1.300	0.690	.56350	0.970	1.010	0.630	.32311	0.330	0.400	0.300	.02073	47.33
  87	13-Jan				.00000				.00000				.00000
  88	14-Jan				.00000				.00000				.00000

  89	15-Jan	Died 1/15/96	#VAL-	Died 1/15/96	#VAL-	Died 1/15/96	#VAL-
  			UE!		UE!		UE!

  	T-1 AVERAGE GROWTH	T-2 AVERAGE GROWTH	T-3 AVERAGE GROWTH

  	0.740	0.593	0.399	0.142	0.638	0.658	0.369	0.112	0.357	0.328	0.254	0.018

• [0194]

  DOB 3/25/95	A-540 NECK T-1		A-540 T-2		WEIGHT	HE

  DAY	DATE	X	Y	Z	EVOL	X	Y	Z	EVOL	GRAMS	CT

  1	15-Nov	0.280	0.260	0.210	.00800		.00000	29.97	40
  2	16-Nov	0.290	0.280	0.230	.00978		.00000	30.89
  3	17-Nov	0.290	0.290	0.230	.01013		.00000	30.11
  4	18-Nov	0.290	0.290	0.230	.01013		.00000	30.11
  5	19-Nov	0.300	0.290	0.240	.01093		.00000	30.10
  6	20-Nov	0.300	0.290	0.240	.01093		.00000	30.10	41
  7	21-Nov	0.320	0.290	0.240	.01186		.00000	29.92
  8	22-Nov	0.360	0.340	0.220	.01410		.00000	30.17
  9	23-Nov	0.380	0.360	0.220	.01576		.00000	30.50
  10	24-Nov	0.400	0.370	0.220	.01705		.00000	30.94
  11	25-Nov	0.420	0.390	0.240	.02058		.00000	31.30
  12	26-Nov	0.440	0.410	0.260	.02455		.00000	31.50
  13	27-Nov	0.450	0.430	0.280	.02836		.00000	31.64
  14	28-Nov	0.450	0.430	0.260	.02634		.00000	29.92
  15	29-Nov	0.470	0.440	0.260	.02815		.00000	30.29	29
  16	20-Nov	0.530	0.450	0.260	.03246		.00000	29.83
  17	1-Dec	0.490	0.440	0.300	.03386		.00000	29.61
  18	2-Dec	0.510	0.450	0.320	.03845		.00000	29.90
  19	3-Dec	0.530	0.460	0.330	.04212		.00000	30.38
  20	4-Dec	0.550	0.470	0.340	.04601		.00000	30.78
  21	5-Dec	0.550	0.460	0.340	.04503		.00000	29.63
  22	6-Dec	0.550	0.500	0.340	.04895		.00000	30.60	28
  23	7-Dec	0.570	0.530	0.370	.05852		.00000	30.06
  24	8-Dec	0.580	0.550	0.400	0.6680		.00000	29.97
  25	9-Dec	0.600	0.570	0.400	.07161		.00000	29.94
  26	10-Dec	0.600	0.590	0.400	.07413		.00000	29.83
  27	11-Dec	0.610	0.610	0.400	.07792		.00000	29.91
  28	12-Dec	0.650	0.620	0.410	.08650		.00000	30.50
  29	13-Dec	0.680	0.630	0.410	.09195		.00000	31.26	26
  30	14-Dec	0.700	0.650	0.430	.10242		.00000	30.47
  31	15-Dec	0.720	0.680	0.450	.11534		.00000	36.56
  32	16-Dec	0.740	0.680	0.440	.11591		.00000	35.20
  33	17-Dec	0.760	0.690	0.440	.12079		.00000	34.00
  34	18-Dec	0.800	0.690	0.430	.12426		.00000	33.38
  35	19-Dec	0.820	0.710	0.440	.13410		.00000	33.00
  36	20-Dec	0.840	0.720	0.450	.14248		.00000	32.69	19
  37	21-Dec	0.750	0.890	0.450	.15725		.00000	34.22
  38	22-Dec	0.810	0.790	0.650	.21774		.00000	35.08
  39	23-Dec	0.850	0.820	0.670	.24447		.00000	35.60
  40	24-Dec	0.890	0.850	0.690	.27326		.00000	36.20
  41	25-Dec	0.930	0.880	0.710	.30419		.00000	36.80
  42	26-Dec	1.000	0.910	0.730	.34776		.00000	37.90
  43	27-Dec	1.060	0.950	0.740	.39010		.00000	38.77	26
  44	28-Dec	1.070	0.980	0.720	.39524		.00000	38.00
  45	29-Dec	1.090	0.910	0.700	.36348		.00000	37.47
  46	30-Dec	1.090	0.910	0.700	.36348		.00000	36.00
  47	31-Dec	1.100	0.910	0.700	.36682		.00000	34.50
  48	1-Jan	1.100	0.910	0.700	.36682		.00000	33.08

  49

  2-Jan

  Died 01/02/96

  #VAL-

  .00000

  50

  T-1 AVERAGE GROWTH

  	0.637	0.584	0.413	0.119

• [0195]

  DOB 03/25/95	A-542 NECK T-1		A-542 LT ARM T-2		WEIGHT	HE

  DAY	DATE	X	Y	Z	EVOL	X	Y	Z	EVOL	GRAMS	CT
  1	27-Nov	0.350	0.400	0.360	.02638				.00000	28.99
  2	28-Nov	0.370	0.410	0.370	.02938				.00000	29.65
  3	29-Nov	0.400	0.450	0.400	.03769				.00000	29.47	40
  4	30-Nov	0.440	0.480	0.430	.04754				.00000	29.26
  5	1-Dec	0.470	0.500	0.400	.04921				.00000	29.68
  6	2-Dec	0.480	0.520	0.410	.05357				.00000	29.90
  7	3-Dec	0.490	0.540	0.430	.05956				.00000	30.20
  8	4-Dec	0.500	0.550	0.440	.06334				.00000	30.36
  9	5-Dec	0.510	0.550	0.440	.06461				.00000	30.19
  10	6-Dec	0.510	0.550	0.450	.06608				.00000	30.73	40
  11	7-Dec	0.550	0.580	0.470	.07849				.00000	31.18
  12	8-Dec	0.550	0.620	0.480	.08569				.00000	31.69
  13	9-Dec	0.570	0.690	0.490	.10089				.00000	32.20
  14	10-Dec	0.590	0.760	0.510	.11972				.00000	32.90
  15	11-Dec	0.610	0.830	0.520	.13782				.00000	33.33
  16	12-Dec	0.650	0.845	0.530	.15239				.00000	33.90
  17	13-Dec	0.690	0.860	0.520	.16154	0.300	0.240	0.150	.00565	34.59	34
  18	14-Dec	0.710	0.920	0.540	.18465	0.300	0.240	0.150	.00565	35.65
  19	15-Dec	0.720	0.890	0.550	.18450	0.280	0.270	0.150	.00594	35.39
  20	16-Dec	0.800	0.940	0.580	.22833	0.280	0.270	0.210	.00831	36.00
  21	17-Dec	0.890	0.980	0.600	.27396	0.270	0.270	0.260	.00992	36.80
  22	18-Dec	0.960	1.010	0.620	.31470	0.270	0.270	0.300	.01145	37.56
  23	19-Dec	0.920	1.050	0.650	.32871	0.250	0.260	0.250	.00851	38.75
  24	20-Dec	0.890	1.090	0.690	.35041	0.190	0.250	0.200	.00497	40.02	33
  25	21-Dec	0.910	1.120	0.690	.36815	0.240	0.260	0.200	.00653	40.04
  26	22-Dec	0.960	1.010	0.610	.30953	0.230	0.380	0.200	.00915	39.57
  27	23-Dec	0.960	1.010	0.600	.30455	0.230	0.380	0.200	.00915	38.80
  28	24-Dec	0.960	1.010	0.600	.30455	0.220	0.380	0.200	.00875	38.20
  29	25-Dec	0.950	1.010	0.590	.29636	0.220	0.380	0.200	.00875	37.60
  30	26-Dec	0.950	1.010	0.590	.29636	0.210	0.380	0.200	.00836	37.00
  31	27-Dec	0.940	1.010	0.590	.29324	0.200	0.380	0.190	.00756	36.36	32
  32	28-Dec	0.950	1.015	0.530	.26754	0.225	0.380	0.210	.00940	37.40
  33	29-Dec	0.960	1.020	0.450	.23068	0.250	0.390	0.220	.01123	38.52
  34	30-Dec	0.970	1.040	0.470	.24821	0.270	0.400	0.220	.01244	39.10
  35	31-Dec	0.980	1.070	0.480	.26349	0.290	0.410	0.230	.01432	39.70
  36	1-Jan	0.980	1.090	0.490	.27401	0.320	0.410	0.230	.01580	40.20
  37	2-Jan	0.980	1.110	0.520	.29612	0.320	0.430	0.240	.01729	41.92
  38	3-Jan	0.960	1.140	0.510	.29219	0.340	0.470	0.240	.02008	43.00	30
  39	4-Jan	0.930	1.260	0.520	.31899	0.360	0.470	0.260	.02303	46.30
  40	5-Jan	0.960	1.110	0.520	.29008	0.400	0.470	0.270	.02657	37.13
  41	6-Jan	0.960	1.110	0.540	.30123	0.440	0.490	0.310	.03499	37.40
  42	7-Jan	0.960	1.110	0.560	.31239	0.480	0.510	0.350	.04485	37.80
  43	8-Jan	0.960	1.100	0.580	.32063	0.530	0.530	0.390	.05735	38.10
  44	9-Jan	0.960	1.100	0.600	.33169	0.570	0.540	0.410	.06606	38.40
  45	10-Jan	0.960	1.100	0.620	.34275	0.610	0.550	0.430	.07552	38.60	30
  46	11-Jan	0.960	1.100	0.620	.34275	0.660	0.550	0.440	.08361	38.80
  47	12-Jan	0.950	1.000	0.630	.31331	0.650	0.570	0.430	.08340	38.84
  48	13-Jan	0.990	1.000	0.630	.32651	0.710	0.590	0.440	.09549	39.80
  49	14-Jan	1.020	1.010	0.620	.33437	0.780	0.600	0.450	.11025	40.70
  50	15-Jan	1.050	1.010	0.620	.34421	0.840	0.610	0.450	.12071	41.65
  51	16-Jan	1.040	0.970	0.620	.32743	0.830	0.640	0.460	.12792	42.40
  52	17-Jan	1.040	0.990	0.580	.31262	0.870	0.640	0.470	.13700	40.85	30

  53	18-Jan	Died 1/18/96	#VAL-	Died 1/18/96	#VAL-
  			UE!		UE!

  54

  19-Jan

  T-1 AVERAGE GROWTH

  T-2 AVERAGE GROWTH

  55	20-Jan	0.803	0.897	0.536	0.226	0.401	0.424	0.284	0.034

• [0196]

  			A-592 LT
  DOB 6/27/95	A-592 LT LEG T-1		ARMPIT T-2		A-592 RT ARM T-3		WEIGHT	HE

  DAY	DATE	X	Y	Z	EVOL	X	Y	Z	EVOL	X	Y	Z	EVOL	GRAMS	CT
  1	16-Jan	0.480	0.380	0.170	.0162				.0000				.0000	32.86
  2	17-Jan	0.530	0.380	0.200	.0211	0.210	0.200	0.110	.0024				.0000	31.03	41
  3	18-Jan	0.550	0.430	0.220	.0272	0.200	0.200	0.100	.0021				.0000	31.64
  4	19-Jan	0.560	0.440	0.220	.0284	0.200	0.200	0.100	.0021				.0000	30.94
  5	20-Jan	0.620	0.480	0.250	.0389	0.200	0.190	0.100	.0020				.0000	30.60
  6	21-Jan	0.680	0.530	0.280	.0528	0.200	0.190	0.100	.0020				.0000	31.20
  7	22-Jan	0.740	0.570	0.300	.0662	0.200	0.180	0.100	.0019				.0000	31.98
  8	23-Jan	0.800	0.610	0.300	.0766	0.190	0.170	0.100	.0017				.0000	32.51
  9	24-Jan	0.810	0.670	0.300	.0852	0.200	0.180	0.110	.0021				.0000	34.80	35
  10	25-Jan	0.830	0.680	0.310	.0916	0.200	0.210	0.110	.0024				.0000	36.02
  11	26-Jan	0.920	0.750	0.340	.1228	0.200	0.210	0.110	.0024				.0000	35.83
  12	27-Jan	0.950	0.750	0.350	.1305	0.200	0.210	0.110	.0024				.0000	36.80
  13	28-Jan	0.890	0.750	0.350	.1360	0.190	0.200	0.110	.0022				.0000	37.80
  14	29-Jan	1.030	0.750	0.460	.1860	0.190	0.200	0.110	.0022	0.260	0.270	.0080	.0029	38.59
  15	30-Jan	1.110	0.810	0.490	.2306	0.210	0.200	0.110	.0024	0.260	0.280	0.090	.0034	42.38
  16	31-Jan	1.150	0.850	0.500	.2559	0.240	0.200	0.110	.0028	0.260	0.290	0.120	.0047	42.30	25
  17	1-Feb	1.170	0.840	0.540	.2778	0.230	0.200	0.110	.0026	0.280	0.300	0.120	.0053	42.44
  18	2-Feb	1.220	1.000	0.590	.3768	0.250	0.260	0.110	.0037	0.270	0.290	0.120	.0049	44.98
  19	3-Feb	1.340	1.070	0.610	.4579	0.250	0.260	0.110	.0037	0.290	0.290	0.120	.0053	45.97
  20	4-Feb	1.360	1.100	0.650	.5091	0.230	0.250	0.110	.0033	0.310	0.300	0.140	.0068	46.80
  21	5-Feb	1.480	1.140	0.690	.6094	0.220	0.240	0.120	.0033	0.330	0.300	0.150	.0078	48.63
  22	6-Feb	1.430	1.150	0.710	.6112	0.220	0.240	0.120	.0033	0.340	0.310	0.150	.0083	50.98
  23	7-Feb	1.500	1.200	0.760	.7161	0.220	0.240	0.120	.0033	0.360	0.340	0.160	.0103	51.25	20
  24	8-Feb	1.520	1.240	0.760	.7499	0.200	0.210	0.120	.0026	0.360	0.340	0.160	.0103	53.65
  25	9-Feb	1.600	1.250	0.760	.7957	0.210	0.210	0.130	.0030	0.360	0.340	0.160	.0103	54.20
  26	10-Feb	1.640	1.270	0.760	.8287	0.220	0.210	0.130	.0031	0.360	0.350	0.160	.0106	54.80
  27	11-Feb	1.680	1.290	0.760	.8622	0.230	0.220	0.130	.0034	0.360	0.360	0.170	.0115	56.40
  28	12-Feb	1.750	1.300	0.760	.9051	0.240	0.220	0.140	.0039	0.360	0.370	0.170	.0119	56.06
  29	13-Feb	1.700	1.340	0.760	.9053	0.220	0.220	0.120	.0030	0.360	0.360	0.170	.0115	50.11
  30	14-Feb	1.680	1.350	0.690	.8192	0.220	0.260	0.140	.0042	0.380	0.360	0.210	.0150	50.57

  31	15-Feb	Died 2/15/96	#VAL-	Died 2/15/96	#VAL-	Died 2/15/96	#VAL-
  			UE!		UE!		UE!

• [0197]

  DOB 6/27/95	A-594 RT SIDE T-1		A-594 T-2		WEIGHT	HE

  DAY	DATE	X	Y	Z	EVOL	X	Y	Z	EVOL	GRAMS	CT
  1	12-Jan	0.160	0.200	0.090	.00151				.00000	41.92
  2	13-Jan	0.200	0.210	0.090	.00198				.00000	41.40
  3	14-Jan	0.240	0.220	0.100	.00276				.00000	40.80
  4	15-Jan	0.270	0.230	0.100	.00325				.00000	40.20
  5	16-Jan	0.270	0.220	0.090	.00283				.00000	39.95
  6	17-Jan	0.280	0.230	0.100	.00337				.00000	39.73
  7	18-Jan	0.260	0.240	0.110	.00359				.00000	39.49
  8	19-Jan	0.280	0.280	0.140	.00575				.00000	39.60
  9	20-Jan	0.300	0.280	0.150	.00660				.00000	39.10
  10	21-Jan	0.340	0.290	0.150	.00774				.00000	38.50
  11	22-Jan	0.360	0.290	0.160	.00874				.00000	38.06
  12	23-Jan	0.390	0.300	0.230	.01409				.00000	39.57
  13	24-Jan	0.450	0.340	0.240	.01922				.00000	39.28	43
  14	25-Jan	0.400	0.360	0.260	.02254				.00000	39.32
  15	26-Jan	0.500	0.390	0.290	.02960				.00000	39.09
  16	27-Jan	0.520	0.420	0.290	.03316				.00000	38.80
  17	28-Jan	0.530	0.440	0.290	.03540				.00000	38.30
  18	29-Jan	0.550	0.470	0.290	.03924				.00000	37.97
  19	30-Jan	0.560	0.490	0.290	.04166				.00000	38.79
  20	31-Jan	0.590	0.530	0.340	.05566				.00000	38.82	38
  21	1-Feb	0.640	0.570	0.340	.08493				.00000	39.08
  22	2-Feb	0.670	0.610	0.360	.07702				.00000	39.85
  23	3-Feb	0.700	0.640	0.370	.06678				.00000	39.65
  24	4-Feb	0.740	0.670	0.360	.09344				.00000	39.90
  25	5-Feb	0.790	0.700	0.360	.10422				.00000	40.20
  26	6-Feb	0.860	0.790	0.300	.10670				.00000	39.53
  27	7-Feb	0.920	0.940	0.340	.15393				.00000	38.66	32
  28	8-Feb	1.020	1.010	0.290	.15640				.00000	37.37
  29	9-Feb	1.030	1.030	0.290	.15106				.00000	36.40
  30	10-Feb	1.050	1.050	0.280	.16160				.00000	35.00
  31	11-Feb	1.060	1.070	0.280	.16625				.00000	33.50
  32	12-Feb	1.070	1.080	0.280	.16939				.00000	31.95
  33	13-Feb	1.110	1.060	0.310	.19094				.00000	30.87
  34	14-Feb	1.110	1.100	0.270	.17258				.00000	33.88	20
  35	15-Feb	1.170	1.090	0.270	.18026				.00000	34.31

  36	16-Feb	Died 2/16/96	#VAL-		.00000
  			UE!

APPENDIX C TREATED MOUSE DATA (EXTERNAL MODULATOR EMBODIMENT)
• [0198]

  Index (Pages numbered on back)

  Appendix	Subject	Pages
  C1	OUJ-738	116

• [0199]

  	T-1 Lt Underarm	Vol	WEIGHT	HEMATO-		TREATMENT PARAMETERS

  DAY	DATE	Ln	Wd	Ht	T-1	Gr	CRIT-%	DEVICE	FREQ MHz	POWER	TIME	FREQ MHz
  1	5-Mar	0.110	0.110	0.110	.00070	37.95		8662A	43351855.0			43353800.0
  2	6-Mar	0.110	0.110	0.110	.00070	36.83		8662A	43351855.0			43353800.0
  3	7-Mar	0.100	0.110	0.100	.00058	36.00		8662A	43351855.0			43353800.0
  4	8-Mar	0.110	0.100	0.100	.00058	36.02	46	8662A	43351855.0			43353800.0
  5	9-Mar	0.110	0.100	0.100	.00058	36.25			NO TREATMENT			NO TREATMENT
  6	10-Mar	0.100	0.100	0.100	.00052	36.56		8662A	43351855.0			43353800.0
  7	11-Mar	0.110	0.100	0.090	.00052	35.32		8662A	43351855.0			43353800.0
  8	12-Mar	0.110	0.110	0.080	.00051	34.88		8662A	43346000.0			43353800.0
  9	13-Mar	0.120	0.120	0.070	.00053	35.11		8662A	43351855.0			43346000.0
  10	14-Mar	0.130	0.120	0.070	.00057	34.91		8662A	43351855.0			43353800.0
  11	15-Mar	0.140	0.130	0.060	.00057	34.84	44	8662A	43351855.0			43353800.0
  12	16-Mar	0.145	0.130	0.065	.00064	35.20			NO TREATMENT			NO TREATMENT
  13	17-Mar	0.150	0.130	0.070	.00071	35.58		8662A	43351855.0			43353800.0
  14	18-Mar	0.150	0.130	0.070	.00071	35.25		8662A	43351855.0			43353800.0
  15	19-Mar	0.150	0.120	0.070	.00066	33.66		8662A	43351855.0			43353800.0
  16	20-Mar	0.160	0.120	0.070	.00070	33.81		8662A	43351855.0			43353800.0
  17	21-Mar	0.160	0.120	0.070	.00070	32.67		8662A	43351855.0			43353800.0
  18	22-Mar	0.160	0.130	0.070	.00076	32.83	43	8662A	43351855.0			43353800.0
  19	23-Mar	0.160	0.130	0.070	.00076	33.23			NO TREATMENT			NO TREATMENT
  20	24-Mar	0.170	0.130	0.080	.00093	33.63		8662A	43351855.0			43353800.0
  21	25-Mar	0.180	0.130	0.080	.00098	33.01		8662A	43351855.0			43353800.0
  22	26-Mar	0.190	0.130	0.070	.00091	32.69		8662A	43351855.0			43353800.0
  23	27-Mar	0.190	0.130	0.080	.00103	31.25		8662A	43351855.0			43353800.0
  24	28-Mar	0.190	0.130	0.080	.00103	31.63		8662A	43351855.0			43353800.0
  25	29-Mar	0.190	0.130	0.080	.00103	31.11	44	8662A	43351855.0			43353800.0
  26	30-Mar	0.190	0.130	0.080	.00103	31.36			NO TREATMENT			NO TREATMENT
  27	31-Mar	0.200	0.130	0.070	.00095	31.64		8662A	43351855.0			43353800.0
  28	1-Apr	0.210	0.130	0.070	.00100	31.83		8662A	43351855.0			43353800.0
  29	2-Apr	0.210	0.130	0.070	.00100	31.11		8662A	43351855.0			43353800.0
  30	3-Apr	0.210	0.140	0.070	.00108	31.80		8662A	43351855.0			43353800.0
  31	4-Apr	0.220	0.140	0.080	.00129	30.98		8662A	43351855.0			43353800.0
  32	5-Apr				.00000				NO TREATMENT			NO TREATMENT
  33	6-Apr				.00000

  	TREATMENT
  	PARAMETERS

  	DAY	DATE	POWER	TIME	DEVICE
  	1	5-Mar	0.0 dBm	1, 1	SW & HP
  	2	6-Mar	0.0 dBm	1, 1	SW & HP
  	3	7-Mar	0.0 dBm	1, 1	SW & HP
  	4	8-Mar	0.0 dBm	1, 1	SW & HP
  	5	9-Mar
  	6	10-Mar	0.0 dBm	1, 1	SW & NP
  	7	11-Mar	0.0 dBm	1, 1	SW & NP
  	8	12-Mar	0.0 dBm	1, 1	SW & NP
  	9	13-Mar	0.0 dBm	1, 1	SW & NP
  	10	14-Mar	0.0 dBm	1, 1	SW & NP
  	11	15-Mar	0.0 dBm	1, 1	SW & HP
  	12	16-Mar
  	13	17-Mar	0.0 dBm	1, 1	SW & HP
  	14	18-Mar	0.0 dBm	1, 1	SW & HP
  	15	19-Mar	0.0 dBm	1, 1	SW & HP
  	16	20-Mar	0.0 dBm	1, 1	SW & HP
  	17	21-Mar	0.0 dBm	1, 1	SW & HP
  	18	22-Mar	0.0 dBm	1, 1	SW & HP
  	19	23-Mar
  	20	24-Mar	−40 dBm	1, 1	SW & HP
  	21	25-Mar	−50 dBm	1, 1	SW & HP
  	22	26-Mar	0.0 dBm	1, 1	SW & HP
  	23	27-Mar	0.0 dBm	1, 1	SW & HP
  	24	28-Mar	0.0 dBm	1, 1	SW & HP
  	25	29-Mar	0.0 dBm	1, 1	SW & HP
  	26	30-Mar
  	27	31-Mar	0.0 dBm	1, 1	SW & HP
  	28	1-Apr	0.0 dBm	1, 1	SW & HP
  	29	2-Apr	0.0 dBm	1, 1	SW & HP
  	30	3-Apr	0.0 dBm	1, 1	SW & HP
  	31	4-Apr	0.0 dBm	1, 1	SW & HP
  	32	5-Apr
  	33	6-Apr

Claims (19)

We claim:

1. Therapeutic apparatus, comprising

means for generating an approximately 60 Hz., 50% duty cycle square wave signal pulsed at a second 50% duty cycle at approximately 1.167 Hz.,

a quartz crystal with a resonant frequency in the radio frequency range, serially driven by said signal,

a wire loop, the input of which is serially driven by the output of said quartz crystal, and the other end of which is grounded with respect to said square wave generating means.

2. The apparatus of claim 1, wherein the frequency of the crystal is selected from the group of frequencies consisting of: 43,322,480 Hz., 43,322,492 Hz., 43,322,485 Hz., 43,346,000 Hz., 43,346,090 Hz., 43,346,000 Hz., 43,346,050 Hz., 43,353,800 Hz., 43,353,800 Hz., 43,353,850 Hz., 43,353,800 Hz., 43,296,000 Hz., 43,351,830 Hz., 43,351,850 Hz., 43,351,855 Hz., 43,351,870 Hz., 43,352,000 Hz., and 43,245,000 Hz., all ±20 Hz.

3. The apparatus of claim 1, wherein the means for generating said approximately 60 Hz., 50% duty cycle square wave signal pulsed at a second 50% duty cycle at approximately 1.167 Hz. comprises

means for generating a first square wave of approximately 60 Hz., at a duty cycle of approximately 50%,

means for generating a second square wave of approximately 1.167 Hz., at a duty cycle of approximately 50%, and

means for ANDing said first square wave and said second square wave.

4. The apparatus of claim 3, wherein between said ANDing means and said crystal there is inserted a series LC filtering means comprising an inductor and a variable capacitor.

5. The apparatus of claim 4, wherein said wire loop is made from approximately five turns spaced approximately 3.175 mm. apart of a wire approximately 60 cm. long.

6. The apparatus of claim 5, wherein said wire loop is mounted on the housing of the apparatus.

7. The apparatus of claim 6, wherein the power supply for the apparatus comprises a battery housed within the apparatus so as to render the apparatus self-contained.

8. The apparatus of claim 6, wherein the power supply for the apparatus comprises an external, power line driven transformer.

9. Therapeutic apparatus, comprising,

a stable frequency generator means having a modulation input, a range of radio frequency outputs, the ability to provide output at a steady power of 1 mw or less, and the ability to provide radio frequency output tunable to at least one half a part per million,

a modulator, connected to said modulation input, providing an approximately 60 Hz., 50% duty cycle square wave signal pulsed at a second 50% duty cycle at approximately 1.167 Hz., and

a wire loop, one end of which is connected to the output of said frequency generator means, and the other end of which is grounded with respect to said frequency generator means.

10. The apparatus of claim 9, wherein said radio frequency output is selected from the group of frequencies consisting of: 43,322,480 Hz., 43,322,492 Hz., 43,322,485 Hz., 43,346,000 Hz., 43,346,090 Hz., 43,346,000 Hz., 43,346,050 Hz., 43,353,800 Hz., 43,353,800 Hz., 43,353,850 Hz., 43,353,800 Hz., 43,296,000 Hz., 43,351,830 Hz., 43,351,850 Hz., 43,351,855 Hz., 43,351,870 Hz., 43,352,000 Hz., and 43,245,000 Hz., all ±20 Hz.

11. The apparatus of claim 9, wherein said modulator comprises

means for generating a first square wave of approximately 60 Hz. at a duty cycle of approximately 50%,

means for generating a second square wave of approximately 1.167 Hz. at a duty cycle of approximately 50%, and

means for ANDing said first square wave and said second square wave.

12. Therapeutic apparatus, comprising,

a stable frequency generator means having a range of radio frequency outputs, the ability to provide output at a steady power of 1 mw or less, and the ability to provide radio frequency output tunable to at least one half a part per million,

a modulator, connected in series to the radio frequency output of said modulation input, providing an approximately 60 Hz., 50% duty cycle square wave signal pulsed at a second 50% duty cycle at approximately 1.167 Hz., and

a wire loop, one end of which is connected to the output of said frequency generator means, and the other end of which is grounded with respect to said frequency generator means.

13. The apparatus of claim 12, wherein said radio frequency output is selected from the group of frequencies consisting of: 43,322,480 Hz., 43,322,492 Hz., 43,322,485 Hz., 43,346,000 Hz., 43,346,090 Hz., 43,346,000 Hz., 43,346,050 Hz., 43,353,800 Hz., 43,353,800 Hz., 43,353,850 Hz., 43,353,800 Hz., 43,296,000 Hz., 43,351,830 Hz., 43,351,850 Hz., 43,351,855 Hz., 43,351,870 Hz., 43,352,000 Hz., and 43,245,000 Hz., all ±20 Hz.

14. The apparatus of claim 12, wherein said modulator comprises

means for generating a first square wave of approximately 60 Hz. at a duty cycle of approximately 50%,

means for generating a second square wave of approximately 1.167 Hz. at a duty cycle of approximately 50%,

means for ANDing said first square wave and said second square wave, and

means responsive to said ANDed first and second square wave for switching a series radio frequency signal.

15. The apparatus of claim 12 wherein, said wire loop is connected to the output of said frequency generator means by a Hewlett-Packard 10501A or equivalent shielded coaxial cable.

16. A method for treating cancer and other illnesses in a human or animal subject, comprising,

generating a radio frequency signal tuned to a treatment frequency that has been specified to a precision of at least one half of a part per million;

modulating said radio frequency with an approximately 60 Hz. square wave with an approximately 50% duty cycle which has been gated by an approximately 1.167 Hz. square wave with an approximately 50% duty cycle

applying said modulated radio frequency signal at a power of 1 mw or less to one end of a wire loop and grounding the other end of said loop,

placing said wire loop to which said modulated radio frequency signal has been applied on the surface of the subject's body for a period of at least one hour.

17. The method of claim 16, wherein said radio frequency is selected from the group of frequencies consisting of: 43,322,480 Hz., 43,322,492 Hz., 43,322,485 Hz., 43,346,000 Hz., 43,346,090 Hz., 43,346,000 Hz., 43,346,050 Hz., 43,353,800 Hz., 43,353,800 Hz., 43,353,850 Hz., 43,353,800 Hz., 43,296,000 Hz., 43,351,830 30 Hz., 43,351,850 Hz., 43,351,855 Hz., 43,351,870 Hz., 43,352,000 Hz., and 43,245,000 Hz., all ±20 Hz.

18. The method of claim 16, wherein said wire loop is made from approximately five turns spaced approximately 3.175 cm. apart of a wire approximately 60 cm. long

19. A low power, precisely tuned, stable RF generator comprising,

means for generating a sequence of audio frequency square waves, and

a quartz crystal tuned to an RF frequency, connected in series to said square wave generating means.

Images